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Abstract and Keywords
The chemotherapy drug ifosfamide is used in the treatment of several childhood
cancers. While effective, its use in children results in a 30% incidence of
nephrotoxicity, and 5% incidence of Fanconi syndrome. This late effect is caused by
oxidative damage, generated by chloroacetaldehyde, a toxic metabolite of ifosfamide
cytochrome P450-mediated bioactivation in the kidney tubules. N-acetylcysteine has
been identified as a promising strategy to mitigate nephrotoxicity through its
antioxidant and glutathione stimulating properties. Furthermore, with current use in
children for acetaminophen poisoning, its clinical utility is evident. Both cell and animal
models have demonstrated n-acetylcysteine’s effectiveness in mitigating ifosfamide
kidney toxicity. However, there is no data available to suggest the safe use of nacetylcysteine with respect to maintenance of ifosfamide’s chemotherapeutic integrity.
There is also a lack of information suggesting that the current dose for acetaminophen
overdose will be sufficient for the alternative indication of renal protection. To address
this gap in knowledge, which is critical in moving forward with the use of nacetylcysteine in a clinical setting, herein I describe three studies, which focus on the
translational pharmacokinetics of n-acetylcysteine, as well as its effect on the efficacy
of ifosfamide. Using a comparison of our therapeutically effective rodent model to
children receiving the 21-hour intravenous dose of n-acetylcysteine for acetaminophen
overdose, we were able to demonstrate similar systemic exposures are achieved in both
groups. This corroborates that the dose currently used in children is an excellent choice
for renal protection. To demonstrate the impact of n-acetylcysteine on the antitumor
efficacy of ifosfamide, we evaluated the combination of n-acetylcysteine and ifosfamide
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mustard, the active antineoplastic agent in vitro and n-acetylcysteine and ifosfamide in a
mouse xenograft model. Our investigations provide evidence to suggest nacetylcysteine does not interfere with ifosfamide activity, further supporting its safe use.
Based on existing evidence, including that presented in this thesis, we have developed
clinical protocol recommendations, for the safe use of n-acetylcysteine for children who
present with renal toxicity due to ifosfamide. I also detail a randomized prospective
double-blinded study designed to assess the effectiveness of n-acetylcysteine as a
prophylactic strategy, in a control fashion.

Keywords: ifosfamide, nephrotoxicity, n-acetylcysteine, pharmacokinetics, antitumour
efficacy, translational research
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Chapter 1: Introduction and Rationale
Part of the chapter has been published:
Hanly L, Chen N, Rieder M, Koren G. Ifosfamide nephrotoxicity in children; a
mechanistic base for pharmacological prevention. Expert Opinion on Drug Safety 2009;
8(2): 155-168.
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1.1 Overview
Ifosfamide (IFO) is a chemotherapeutic agent used over the past 2 decades for
therapy of various adult and pediatric solid tumors [1-3]. In recent years, its use in
pediatric solid tumors such as Ewing’s sarcoma, rhabdomyosarcoma, lymphoma,
neuroblastoma, osteosarcoma, soft tissue sarcomas and Wilms tumor has rapidly
increased [3-6] owing to greater antineoplastic activity than its analogue
cyclophosphamide (CF) [7], greater cure rate and a higher therapeutic index, with
relatively rare cross-resistance [8]. Patients who may not respond to CF treatment may
still benefit from IFO [9,10]. However, IFO versus CF treatment still needs further
investigation clinically. Its mode of cytotoxic effect is by acting as a bifunctional DNA
alkylating agent, causing both inter and intra DNA strand cross-links. It can also cause
cross-links between protein and DNA with these events ultimately preventing cellular
replication, leading to cell death [11].
IFO is a pro-drug that needs to be oxidized intracellularly to the cytoactive IFO
mustard. In addition, when metabolized by the cytochrome P450 (CYP) monooxygenase
system in both liver [1] and kidney [12,13], it gives rise to the toxic metabolites acrolein
and chloroacetaldehyde (CAA), the reactive metabolites responsible for IFO associated
urotoxicity and nephrotoxicity, respectively [14-16]. The urotoxic effects of acrolein have
been well mitigated by sodium 2-mercaptoethanesulfonate (MESNA) given concurrently
with IFO. Presently, nephrotoxicity is the biggest concern during IFO treatment [6],
especially in children. Up to 30% of children treated with IFO may suffer from some
degree of renal damage. Although studies have yielded conflicting estimates of the risk
involved with young age and IFO treatment, current research suggests that age [17,18]
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along with cumulative dose [19-23], prior/concurrent cisplatin treatment and unilateral
nephrectomy [23-25] are all risk factors for IFO-induced renal injury. Although it has
shown potent effects as an antineoplastic agent, severe renal damage may seriously
impact the quality of life and well being of children who survive cancer.

1.2 Ifosfamide metabolism
IFO is almost identical in structure to CF (Figure 1.1), varying only in the position
of one chloroethyl group [26,27]. Metabolism of both occurs by the CYP isozymes 3A4,
3A5 and 2B6 [9,10,28], resulting in similar metabolites. There are only few quantitative
differences due to variation in the rates of biotransformation [14]. Ring hydroxylation of
ifosfamide produces 4-hydroxy-ifosfamide, in equilibrium with aldo-ifosfamide (Figure
1.2 ). Aldo-ifosfamide then spontaneously converts to the active metabolite IFO mustard
and equimolar amounts of acrolein, or becomes dehydrogenated to inactive carboxyifosfamide. Acrolein is recognized as the toxic metabolite responsible for IFO-induced
urotoxicity [15].
A certain percentage of IFO and CF also undergoes metabolism through an
alternative pathway: oxidation of the chloroethyl side chain leads to 2 -and 3dechloroethyl-ifosfamide or 2- and 3-decholoroethyl-cyclofosfamide and equal amounts
of CAA [16]. There is a large body of evidence that CAA is responsible for IFO-induced
nephrotoxicity [29-31].

4

Figure 1.1 CF and IFO chemical structures, differing in the position of one chloroethyl
group.

5
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Figure 1.2 IFO metabolism. Ring hydroxylation and side- chain oxidation of IFO results
in ifosfamide mustard, and 2- and 3-dechloroethyl IFO and CAA, respectively.
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1.2.1 Qualitative difference in ifosfamide versus cyclophosphamide metabolism
Although both CF and IFO undergo the ring hydroxylation pathway, it occurs
much slower in IFO owing to steric hindrance caused by the differentially positioned
chloroethyl group [32]. This allows for a greater proportion of IFO to be metabolized by
an alternative side chain pathway. Hence up to 50% of IFO metabolism occurs through
the side chain pathway producing CAA, although it only accounts for 10% of metabolism
in CF [16]. Consequently, IFO also requires a greater therapeutic dose (up to threefold or
more) to produce the same amount of alkylating agent when compared to CF. This leads
to CAA quantities that are as much as 100-fold higher with IFO than the amounts being
produced from CF [32].
1.2.1 Chloroacetaldehyde
First postulated to be the proximate nephrotoxic agent, studies of CAA area under
the curve (AUC) argued that systemic exposure to CAA alone cannot explain this serious
toxicity. Boddy et al. [33] showed in patients that those with a lower AUC of CAA
exhibited a greater degree of nephrotoxicity. These results led to the conclusion that there
was no correlation between CAA plasma concentrations and kidney damage. However, a
key caveat is that the presence of a metabolite in urine provides no indication of where
this metabolite has been produced. Woodland et al. [14] then hypothesized that local
renal metabolism of IFO to CAA – not systemic exposure – produces renal tubular
damage.
Although other toxic species such as acrolein are produced from IFO, metabolism
studies by Springate and Taub [34] have demonstrated CAA to be the main nephrotoxic
IFO metabolite. Although metabolism is often thought of as hepatic, the kidney possess
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an impressive repertoire of xenobiotic-metabolizing enzymes [12,35], and thus the
potential for production of high concentrations of toxic species by the kidney itself has
come to light [12,13]. The ability of the kidney to ‘produce its own poison’ is, therefore,
a new concept that deserves serious focus in understanding IFO-induced nephrotoxicity
and possibly other drug-induced renal damage. At clinically relevant concentrations, IFO
metabolism occurs in both porcine and human kidney microsomes. This metabolism
occurs consistently with CYP-mediated drug biotransformation [14]. Recent studies have
also shown that both pig and human renal tubules specifically possess the CYP enzymes,
3A4 and 2B6, necessary for CAA production [14,36,37].
Although previous findings demonstrate the capability of renal IFO metabolism,
evidence of clinically relevant amounts of CAA being produced have also been shown. In
vitro, CAA concentrations ranging from 10 to 50 μmol can cause renal tubular toxicity
[30]. Aleksa et al. [38] used pharmacokinetic modeling to evaluate renal tubule
concentrations of CAA. Their findings demonstrate renal tubule cell production of CAA
at levels known to cause tubular damage (50 μmol). This supports the hypothesis that
local renal production of CAA can be responsible for IFO-induced nephrotoxicity. These
findings may also explain how age differences, shown later in this review, may affect
renal metabolism and play a role in inter-individual variability in nephrotoxicity [14].

1.3 Ifosfamide-induced nephrotoxicity
Following the introduction of IFO in the 1970s, interest in its use was reduced
owing to severe cases of hemorrhagic cystitis caused by acrolein [39]. This consequence
of IFO treatment has since been addressed with the concomitant treatment of MESNA.
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The synthetic thiol MESNA chelates acrolein, allowing for protection of the bladder’s
epithelium. Prevention of urotoxicity has allowed for both higher and more frequent dose
schedules of IFO [6]. The elimination of the dose-limiting effect of urotoxicity has
subsequently revealed nephrotoxicity as a serious complication associated with IFO
treatment.
Adults were initially the first group of patients observed to present with IFOinduced nephrotoxicity [18]. In the past decade, however, an awareness of the severity of
nephrotoxicity in children treated with IFO has unfolded [40], causing a shift in this area
of research, with a predominant focus on a younger population. Approximately 30%
[17,18] of children treated with IFO suffer from chronic renal dysfunction with reports as
low as 15% [41] and as high as 60% [40]. Around 1.4 – 5% of these children suffer from
its most severe form, Fanconi syndrome [17,18,41].
1.3.1 Clinical presentation of ifosfamide-induced nephrotoxicity
Nephrotoxicity can present in any one segment or a combination of segments in
the nephron: glomerulus, proximal or distal tubule, or the collecting duct [40]. In the case
of IFO, it most commonly manifests as proximal tubule damage. Glomerular toxicity is
normally secondary to that of tubular [42], although serious distal toxicity is rare [43].
The severity of chronic renal damage can vary from subclinical to severe tubular and/or
glomerular toxicity (Table 1.1). Subclinical features may include glycosuria,
aminoaciduria and increased excretion of low molecular mass proteins [44-48]. More
severe proximal tubule toxicity can result in Fanconi syndrome with clinically relevant
hypophosphatemic rickets, proximal renal tubule acidosis and hypokalemia [19,49-51].
Chronic glomerular dysfunction, evident by reduced glomerular filtration rate (GFR) and
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elevated serum creatinine, may coexist [19,42,49]. Although relatively uncommon [43],
severe distal toxicity, when present, can lead to diabetes insipidus and distal renal tubular
acidosis [51,52].
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Table 1.1 Clinical features and relevant sequelae of IFO-induced nephrotoxicity.
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Proximal Tubular Toxicity
Fanconi syndrome including:
Urinary loss of glucose, amino acids, and Low Molecular Weight proteins
Phosphaturia
Hypophosphatemic Rickets
Kaluria
Hypokalemia
Bicarbonaturia
Proximal Renal Tubular Acidosis
Glomerular Toxicity
Reduced GFR
Increased serum urea and creatinine concentrations
Chronic Renal Failure
Distal Tubular Toxicity
Nephrogenic Diabetes Insipidus
Distal Renal Tubular Acidosis
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1.3.2 Fanconi syndrome
Fanconi syndrome is described as a proximal tubule dysfunction. It consists of
urinary loss of glucose, amino acids and low molecular mass protein as well as
phosphate, bicarbonate and potassium [51,53,54]. Hypophosphatemia resulting from
urinary phosphate loss can develop into hypophosphatemic rickets, a serious metabolic
bone disease [50,54-57]. Proximal renal tubular acidosis, resulting from bicarbonaturia
[20,58], along with hypophosphatemic rickets can lead to serious impairment of growth,
which is especially detrimental to young children [59,60].
1.3.3 Inter-individual variability
Renal toxicity following IFO treatment is subject to great inter-individual
variability. Onset, nature and severity can differ from one patient to the next, with many
suffering no kidney damage although a few suffer from its most severe forms [23,40,50].
Evidence of renal damage may become apparent immediately after starting treatment
[55,56] or not until after the treatment is complete [50,59,61,62]. A follow-up study in 75
patients who had completed IFO treatment found that subclinical damages developed in
the first 2 years after completion of treatment [63]. A diagnosis of Fanconi syndrome was
documented as far as 3 years following cessation of treatment [63]. This has been
supported by previous studies, which found that most patients received a diagnosis of
Fanconi syndrome within 2 years after treatment [49,64].
1.3.4 Long-term outcome and treatment
There is great uncertainty as to the degree of reversibility of renal damage as a
result of IFO treatment [18]. Although some improvement has been seen in tubular
damage [65], most cases are not resolved [17]. In fact, deterioration of tubular [53,56,62]
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and glomerular function [19,42] is commonly seen following cessation of IFO therapy.
There has been one documented case of a child completely recovering from severe
Fanconi syndrome over a 2-year period [66]; no similar reports are yet to be seen in cases
of serious glomerular toxicity. Most cases, however, demonstrate no change, slight
improvement or slight deterioration. A study monitoring glomerular and tubular function
over 10 years in 12 children, showed overall no significant change in either tubular or
glomerular toxicity in the group. However, several individuals showed improvement in
either glomerular filtration rate (GFR) or the severity of phosphaturia, although one
demonstrated deterioration in both. On the whole, nephrotoxicity persisted and there was
no evidence to allow for prediction of how the nephrotoxicity of individuals would
progress [18].
At the present time, treatment of severe proximal tubule toxicity includes
supportive therapy with oral supplementation of phosphate and bicarbonate. In the rare
circumstance of chronic renal failure owing to glomerular toxicity, dialysis or renal
replacement therapy may be required [17]. Treatment of young children is especially
important, as 80% of pediatric cancer patients become long-term cancer survivors [67].
The severe consequences of IFO-induced nephrotoxicity can have a great impact on their
quality of life and well-being.
1.3.5 Ifosfamide-induced nephrotoxicity at a cellular level
Understanding the mechanisms in which CAA exerts its toxic effect on renal
tubule cells is critical to developing effective prevention. CAA has been implicated in the
depletion of ATP levels [68-70], the collapse of the protein gradient through opening of
the mitochondrial permeability transition pores [70,71] and the generation of reactive
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oxygen species (ROS) [72]. It also causes decrease of Na+/K+ ATPase activity [73,74]
and elevation of intracellular Ca2+ [75]. A release of pro-inflammatory cytokines is also
associated with IFO-induced nephrotoxicity [76].
Several studies have demonstrated a significant decrease of ATP in renal tubular
cells following treatment with CAA [68-70]. Not only does ATP have a critical role in
sustaining normal kidney function [77], but also low levels of it initiate necrotic cell
death [78,79], the predominant form of cell death in CAA toxicity [70,75,80]. This
depletion of ATP may be the result of the collapse of the proton gradient in mitochondria
[70]. Following increased intracellular Ca2+ and ROS due to CAA, there is subsequent
induction of the mitochondrial permeability transition pores and, therefore, loss of
mitochondrial membrane potential [71,81]. The ROS responsible are produced by the
reactive metabolite (CAA). These reactive species damage macromolecules, proteins and
DNA, as well as propagate further production of lipid radicals [72]. More specifically in
the context of CAA toxicity, ROS can oxidize proteins on ATPase pumps, rendering
them dysfunctional [82]. Studies have shown that inhibition of Na+ /K+ ATPase occurs in
the renal cells of rats treated with IFO [73,74]. Maintenance of low intracellular levels of
Na+ is critical for normal reabsorption of solutes. Loss of normal Na+ concentration may,
therefore, contribute to urinary loss of solutes in Fanconi syndrome [82]. The increase in
Ca2+ concentration is suggested to occur through the impairment of the Ca2+/Na+
exchanger, therefore, inhibiting its export [75]. Ultimately leading to cell death, elevated
levels of Ca2+ first cause damage to the cell cytoskeleton and membranes, as well as cause
cellular degradation [83].
With respect to the inflammatory response present in IFO-induced nephrotoxicity,
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Sehirli et al. [76] demonstrated an increase in serum concentration of cytokines TNF-α,
IL-β2 and IL6. TNF-α has been suggested to play a role in increasing oxidative stress
through depletion of glutathione (GSH) as seen in pulmonary vascular endothelial cells
[84]. GSH as well as glutathione S-transferase activity has been reported to be depleted in
a number of studies in IFO treated patients [30,85]. TNF-α also increases oxidative stress
through ROS production in human endothelial cells [86], which may, therefore, also
occur in kidney cells subject to CAA toxicity. In necrotic death during the inflammatory
response, release of these cytokines is an expected feature [87]. By clearly defining these
features of IFO-induced nephrotoxicity, caused primarily by oxidative stress, a more
clear direction for future studies toward attenuating nephrotoxicity becomes apparent.

1.4 Risk Factors for ifosfamide-induced nephrotoxicity
There are several risk factors that predispose patients to nephrotoxicity. Age,
cumulative IFO dose [19-22], previous and/or concurrent treatment with cisplatin, and
previous unilateral nephrectomy [23-25] have been suggested as factors that will increase
a patient’s risk of suffering from nephrotoxicity while on IFO treatment regimens. As age
is an important risk factor, many of the published studies have been centered around
children, as they are a more vulnerable population for both nephrotoxicity and its longterm consequences [18].
1.4.1 Age
Several studies have tried to explain the effect of age on nephrotoxicity. Although
Loebstein et al. [88] and Skinner et al. [89] found conflicting results when correlation
nephrotoxicity with age, recent studies on the ontogeny of CYP enzymes 3A and 2B6
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have clarified this issue.
1.4.1.1 Loebstein vs. Skinner
In 2000, Skinner et al. [89] found that in a group of 76 children and adolescents,
for whom all study end points were fully evaluable, there was no correlation between age
and nephrotoxicity associated with IFO. They concluded that in the treatment of IFO,
cumulative dose was the only risk factor in the development of renal toxicity. In contrast,
in a study of 174 evaluable children and young adults, Loebstein et al. [88] found a
negative correlation between age and nephrotoxicity. They found that younger children
were at greater risk for IFO-induced kidney damage, with 41.4% of the 174 patients
demonstrating nephrotoxicity. Although the latter study included children who had
received or were concurrently receiving cisplatin treatment, 51 patients in their study did
not, allowing for statistical analysis of this subgroup. After exclusion of previous or
current cisplatin treatment, 33.5% of children were still observed to suffer from
nephrotoxicity. In this study, renal function was graded as non-nephrotoxic, mildly,
moderately or severely nephrotoxic based on preset criteria. Of the 9.2% of patients who
were graded as having severe nephrotoxicity, all but one was under the age of five. This
study concluded that age is a predictor of both development and severity of
nephrotoxicity and that children younger than 3 years of age are at a greater risk of
developing nephrotoxicity while being treated with IFO. Moreover, there was an apparent
interaction between age and dose rendering children younger than 3 years of age more
sensitive to nephrotoxicity of a given cumulative dose than older children.
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1.4.1.2 Critical review of two opposing studies
A critical review of these two opposing viewpoints has been conducted by Aleksa
et al. (Table 1.2) [90]. Both studies included patients of similar age and health status
[88,89]; however, that of Skinner et al. [89] may not have been adequately powered with
only 67 evaluable patients with pre and post IFO GFR measurements. The time of renal
function assessment differed between the two studies. Patient’s renal function was
assessed before IFO treatment to serve as a baseline, during and 3 months after treatment
in the study by Loebstein et al. [88]. This study also included a 5 year follow-up after the
patients’ first diagnosis. Skinner et al. [89] used a baseline of 105 healthy children and
renal assessment was done only once at an average of 6 months. Aleksa et al. [90]
pointed out that with no baseline and only one assessment, nephrotoxicity as either age or
dose-dependent may be difficult to determine. No baseline data prevents one from
concluding whether biomarkers of nephrotoxicity have increased or decreased in a
specific individual. Follow-up in the study by Skinner et al. [89] may also have been too
short to detect IFO-induced nephrotoxicity [90]. In terms of renal assessment, Skinner et
al. [89] used a more advantageous method by directly measuring GFR by looking at
clearance of 51Cr-labeled ethylenediaminetetraacetic acid (51Cr EDTA) and 99mTc-labeled
diethylenetriaminepentaacetic acid. However, although Loebstein et al. [88] used the less
reliable Schwartz formula, it is commonly used in outpatients and is a much easier
procedure to carry out [90]. Aleksa et al. [90] concluded that young age as a risk factor in
the development of IFO-induced nephrotoxicity should be considered for patients
receiving concomitant cisplatin and that further research in this area needs to be carried
out.
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Table 1.2 Comparison of opposing studies of Loebstein et al. [88] and Skinner et al.
[89].

21

	
  
	
  

Criterion

Loestein et al.

Skinner et al.

Patients
(Fully evaluable)

174 children and
adolescents

76 children and
adolescents

Concurrent cisplatin
treatment

123

3

Baseline

Patients before
treatment

106 healthy children
and adults

Time of renal function
assessment

Before, during and after
(3 months) treatment,
5 year follow-up
(from initial diagnosis)

After treatment (6 months)

Schwartz Formula

Plasma clearance of Cr-EDTA

Nephrotoxicity
grading parameters

GFR, hypophosphatemia,
hypcarbia with acidosis,
glucosuria, and proteinuria

GFR, tubular threshold for
phopohorus serum bicarbonate
morning urine osmolality

Conclusion on age

Age-dependant effect
as a risk factor
found with 41.4% patients
demonstrating renal damage

No age-dependant effect

Glomerular Filtration
Rate Assessment

51
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1.4.2 Renal ontogeny of CYP enzymes
The effect of age on IFO-induced renal toxicity has since been clarified. Young
children have greater renal metabolism of IFO and, therefore, their kidneys are exposed
to higher concentrations of CAA. Young murine animals corresponding to human
toddlers show higher expression of CYP enzymes responsible for IFO metabolism in the
kidney as well as show increased CAA production [91]. The ontogeny of CYP3A and
2B22, which have been cloned and characterized in pig renal tissue [35], were studied by
Aleksa et al. [91] as they are analogues of the two major CYP enzymes 3A4 and 2B6
involved in IFO metabolism. There is 60% homology between the human CYP 3A4 and
porcine 3A [92,93].
Aleksa et al. [91] confirmed the presence of 3A protein in porcine kidneys. Levels
started low between days 0 and 15, significantly increased between days 15 and 60 and
subsequently decreased to adult levels. This corroborates an apparent age dependence of
CYP3A enzyme expression. CYP 2B22 did not show any significant ontogeny from
newborn to adult. Aleksa et al. [91] also measured IFO metabolites to assess the
ontogeny of its metabolism. This was done because ontogeny in protein expression
measured does not necessarily reflect activity, in this case metabolism. CAA levels
demonstrated a trend matching that of CYP3A protein levels. Through days 15 – 60,
metabolism of IFO was significantly greater than newborn (days 0 – 10) and adult (days
> 75) metabolism.
Ultimately, a significant increase in both CYP 3A expression and IFO metabolism
in pigs of age 15 – 60 days was demonstrated, which supports an age-dependant effect on
IFO metabolism. They concluded the effect is due to CYP 3A4 rather than CYP 2B6, as
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2B6 does not show any significant differences with age [91].
The hypothesis that the ontogeny of CYP enzymes may be responsible, at least in
part, for the age-dependant risk associated with IFO treatment has been strengthened by a
study that concluded it is not due to differences in pediatric versus adult tubule
susceptibility to CAA toxicity [68]. Dubourg et al. [68] compared the effects of various
concentrations of CAA on isolated pediatric and adult proximal tubule cells. ATP levels
reflecting cellular metabolism and lactate dehydrogenase released into media as a lysis
marker were measured. GSH and acetyl-CoA plus CoA concentrations, and lactate
metabolism were also evaluated. All measures were compared against each other in both
cell groups following CAA incubation. Both pediatric and adult proximal tubule cells
respond to various CAA concentrations (0.1 – 0.5 mM) in the same way. These results
suggest that there is not a greater sensitivity of pediatric tubules to CAA as once
hypothesized; therefore, it does not explain why younger children are more at risk of
suffering from nephrotoxicity. This further reinforces that it is the ontogeny of CYP
enzymes that is in fact responsible.
1.4.3 Cumulative dose, prior/concurrent nephrotoxin treatment and unilateral
nephrectomy
The dose-dependant effect of IFO treatment is important and well established.
Numerous reports support the suggestion that a higher cumulative IFO dose increases risk
for nephrotoxicity [19,44,88,89]. Although Skinner et al. [89] and Lobstein et al. [88]
had opposing arguments on the role of age in IFO nephrotoxicity; both concluded that
total cumulative dose is important in the development of nephrotoxicity. It has been
suggested that cumulative doses > 60 – 100 g/m2 [19,48] should be avoided in children;
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however, significant renal damage occurred in a cumulative dose as low as 45 g/m2.
This dose caused significant renal damage in patients who were also receiving cisplatin
treatment, another known risk factor for IFO-induced nephrotoxicity. Cisplatin
potentiates the effects of renal damage during IFO treatment, which might explain the
discrepancy in significant cumulative doses seen. This, however, highlights the
importance of considering adverse effects when more than one risk variable comes into
play. Cumulative dose, age [88] and other potentially nephrotoxic treatments when
considered together rather than separate are the best way of assessing the potential of
suffering from nephrotoxicity. As an illustration, Loebstein et al. [88] documented a
significant interaction between dose and age younger than 3 years, rendering younger
children to disproportionately more nephrotoxicity than older children and adults with
similar doses per surface area.
Serious kidney damage due to IFO treatment with previous [24,57] and/or
concomitant [62,94] cisplatin has been repeatedly documented. Responsible for reduced
GFR [95,96], cisplatin treatment may reduce IFO clearance by the kidneys. Other
suggestions include that tubular secretion may be ineffective owing to cisplatin-induced
tubular damage and that there is an inability to convert MESNA to free-thiol form.
Decreased clearance and/or secretion allows for prolonged exposure of the tubules to
toxic metabolites. One study has demonstrated the occurrence of IFO-induced
nephrotoxicity increasing to 41.4 from 33.5% when cisplatin-treated patients were
included in the statistical analysis [88]; however, this increase was not analyzed for
significance.
Severe nephrotoxicity in IFO treatment has also been reported in patients after
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unilateral nephrectomy [23]. Rossi et al. [23] assessed renal function in 120 patients
following IFO treatment to identify risk factors in the development of nephrotoxicity.
Ten of these patients had previously undergone a unilateral nephrectomy. This study
concluded that of all potential risk factors associated with IFO-induced nephrotoxicity,
unilateral nephrectomy was the most important. This observation is well explained by the
single kidney being exposed to the whole body load of circulating IFO rather than to only
50% of it. Although each one of these factors is important to take into account
individually, consideration must also be given to the cumulative and potentially
synergistic effects of the combination of several risk factors. Similarly, consideration of
which risk factor is present is critical, as each one will vary in how it may be dealt with
clinically.

1.5 Prevention of ifosfamide-induced nephrotoxicity
There have been a number of experimental studies conducted in the recent years
in an effort to prevent or attenuate nephrotoxicity associated with IFO treatment.
Although MESNA has been considered as a potential therapy for attenuating
nephrotoxicity as it demonstrates uroprotective properties, it has failed to provide the
same protection in vivo for kidneys [97]. Rapidly oxidizing to DIMESNA on
administration, reduction of its oxidized form in the kidney further depletes GSH [98]. At
present, most of the research in this area has focused on the use of antioxidants as a
protective measure. GSH, a natural antioxidant, is an important defense mechanism of the
cell, providing protection against toxic metabolites such as CAA [99]. Depletion of GSH
has been demonstrated in kidney cells treated with IFO [30], which may already possess
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a greater sensitivity to toxic damage owing to inherently low levels of GSH as compared
to the liver [12]. A recent study by Chen et al. [98] has documented that the depletion of
GSH by L-buthionine sulfoximine greatly increases renal tubular damage of IFO. Use of
antioxidants as a way of compensating for, or inhibiting the depletion of GSH shows
great promise. The antioxidants thymoquinone (TQ) [100], taurine (TAU) [101],
resveratrol (RES) [76], melatonin (MEL) [73], l-histidinol (LH) [102] and nacetylcysteine (NAC) [85] have all been studied in experimental animal models to assess
their ability in preventing IFO-induced nephrotoxicity. Glycine (GLY) has also been
assessed for its protective effects against IFO-induced nephrotoxicity in an animal model
[103].
5.1 Glycine
Demonstrating substantial cellular protection, GLY, when depleted in proximal
tubule cells may predispose them to necrotic damage [104]. GLY depletion has been
proposed to occur as a result of reduced amino acid reabsorption in Fanconi syndrome
[105]. A study by Nissim and Weinberg [103] has demonstrated the nephrotoxicity
attenuating effects of GLY in IFO-treated rats, with plasma concentrations two to
threefold greater than normal. GLY protected renal cells from the phospholipid losses as
seen during IFO treatment, as well as decreased creatinine excretion. Aminoaciduria and
Na+ wasting seemed to improve in GLY treated rats, as was the decrease in plasma HCO3and PO43- seen during IFO treatment. GLY did not, however, protect against all
parameters of IFO-induced nephrotoxicity, more specifically, oxidative stress. ATP and
GSH depletion, and an increase of oxidized GSH during IFO treatment as compared to
controls, showed no change with GLY supplementation. However, importantly, GLY did
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attenuate the severity of tubular function abnormalities. These results suggest that rather
than acting as an antioxidant, GLY acts through alternative mechanisms to provide
cytoprotection; cell integrity and metabolic function preservation occurred through
diminished structural and functional abnormalities. Baines et al. [106] also demonstrated
that GLY improved proximal tubule function in perfused kidneys in areas in which
damage is not usually present. These studies suggest further research on clarifying the
protective mechanisms of GLY as well as its influence on IFO’s antitumor activity is
required.
5.2 Antioxidants
Other compounds that have protected against nephrotoxicity in a rat model seem
to do so through antioxidant properties (Table 1.3). All of the antioxidants studied
attenuated the depletion of GSH and prevented increases in lipid peroxidation in IFOtreated animals [73,76,85,100-102]. TAU, TQ and NAC also prevented the decrease in
glutathione S–transferase activity [85,100,101]. Prevention of free-radical generation was
demonstrated with RES as seen through depression of high luminol, lucigenen Cl and
collagen levels, as seen to occur in renal damage in a study by Sehirli et al. [76]. MEL
also prevented increased levels of collagen, as well as preserved Na+ / K+ ATPase activity
[73].
Although all of the antioxidants prevented urinary loss of at least some of the
solutes seen to occur during nephrotoxicity, only some of the antioxidants prevented low
serum levels of solutes [73,76,85,100-102]. However, when contrasting the protective
effects of each antioxidant on low serum concentrations and urinary loss of solutes,
comparison becomes difficult as each study had slightly different features of
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nephrotoxicity. Some found serum concentrations were not affected by IFO treatment,
whereas others did. As well urine profiles of lost solutes were not the same in each case.
Reduction of both elevated serum creatinine and urea as compared to IFO treated
animals was seen with all antioxidants with the exception of NAC, which did not affect
urea levels [73,76,85,100-102]. However, NAC along with RES and MEL demonstrated
an ability to attenuate the inflammatory response associated with renal damage.
Prevention of interstitial inflammation, increased TNF-α, IL- β2 and IL-6, and neutrophil
infiltrate in IFO treated animals was seen in NAC, RES and MEL respectively. Finally,
both NAC and MEL maintained tubular and glomerular integrity, although RES allowed
for tubular regeneration [73,76,85]. Importantly, the influence of these compounds on
IFO antitumor activity has only been tested in TAU and TQ. TAU does not affect IFO
activity, whereas TQ enhances it [100,101]. The effect of these compounds on the IFO
activity is critical and should be studied in those showing promise for treatment in IFOinduced nephrotoxicity.
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Table 1.3 Comparison of compounds shown to attenuate nephrotoxicity in rats.
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Chemical
Glycine
(Endogenous amino acid)

Taurine
(Endogenous amino acid)

Thymoquinone
(active constituent in the
volatile oil of the black
seed)

L-histidinol
(Structural analogy of
essential amino acid Lhistidine
Melatonin*
(Indolamine produced in
the pineal gland)

Resveratrol*
(Natural phytoalexin
found in grapes, peanuts,
mulberries and red wine)

NAC
(Synthetic precursor of
GSH)

Renal protection
Protection from phospholipid loss
Reduction of urinary solute loss
Reduction of elevated serum creatinine and urea
Maintenance of cell integrity
Cellular protection from oxidative stress
-‐
Prevention of GSH depletion
-‐
Prevention of glutathione S-transferase
activity decrease
-‐
Prevention in rise of lipid peroxidation
(LPO)
Reduction of urinary solute loss
Prevention of low serum phosphate
Reduction of elevated serum creatinine and urea
Cellular protection from oxidative stress
-‐
Prevention of GSH depletion
-‐
Prevention of glutathione S-transferase
activity decrease
-‐
Prevention in rise of LPO
Reduction of urinary solute loss
Prevention in low serum phosphate and albumin
Reduction of elevated serum creatinine and urea
Cellular protection from oxidative stress
-‐
Prevention of GSH depletion
-‐
Prevention in rise of LPO
Reduction of urinary solute loss
Reduction of elevated serum creatinine and urea
Cellular protection from oxidative stress
-‐
Prevention of GSH depletion
-‐
Prevention in rise of LPO
Reduction of urinary solute loss
Prevention in low serum phosphate and albumin
Reduction of elevated serum creatinine and urea
Prevention of neutrophil infiltration
Prevention of collagen increase
Maintenance of Na+/K+ -ATPase activity
Improved tubular and glomerular maintenance
Cellular protection from oxidative stress
-‐
Prevention of GSH depletion
-‐
Prevention in rise of LPO
-‐
Prevention of free radical generation
Reduction of urinary solute loss
Prevention of low serum phosphate, glucose and
albumin
Reduction of elevated serum creatinine, urea, lactate
dehydrogenase activity
Reduction of elevated serum pro-inflammatory
cytokines
Tubular regeneration
Cellular protection from oxidative stress
-‐
Prevention of GSH depletion
-‐
Prevention of gluthatione S-transferase
activity decrease
-‐
Prevention in rise of LPO
Reduction of urinary solute
Prevention of low serum potassium and magnesium
Prevention of elevated serum creatinine
Prevent interstitial inflammation
Prevented tubular and glomerular damage

Influence on IFO antitumor effect
Effect on IFO activity has not been
shown

No effect of IFO antitumor activity

Enhancement of the antitumor
activity of IFO, improving IFO
therapeutic index.

Effect on IFO activity has not been
shown

Melatonin has been shown to not
interfere with antitumor effects of
cisplatin and methotrexate.
Its effects on IFO activity have not
yet been shown.

Effect on IFO activity has not been
shown

Effect on IFO activity has not been
shown
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1.5.3 N-acetylcysteine
Although all of these compounds have shown promise in the attenuation of IFOinduced nephrotoxicity, NAC has a major advantage over other therapies, as it is the
only one presently approved for clinical use in children for other indications. Chen et al.
[85,98] have studied the experimental effectiveness of NAC in the attenuation of IFOinduced nephrotoxicity in vitro and in vivo in a rat model. The choice of NAC in the
treatment of nephrotoxicity of IFO was not only owing to its antioxidant properties;
although NAC shares similar antioxidant properties to many of the others tested in
attenuation of IFO-induced nephrotoxicity (stimulation of GSH, nucleophilic ROS
scavenging properties and enhancement of gluthatione S-transferase activity), it is also a
synthetic precursor for GSH and most importantly is now used clinically in children
[107-109] (Figure 1.3). Presently, NAC is used as an antidote for acetaminophen
posioning; it is commonly used both orally and intravenously with an apparently wide
safety window. There has not been clinical use of the other antioxidants and, therefore,
their safety in children remains in question.
The therapeutic concentration in children receiving NAC for acetaminophen
overdose is 0.4 mM of NAC [107]. This clinically relevant concentration of NAC (0.4
mM) was sufficient in the prevention of IFO-induced nephrotoxicity in vitro [98]. In the
only study of the kinetics of NAC in children, steady-state plasma concentration values
of 0.51 mM have also been reported [110]. Further studies on NAC have been done to
demonstrate that doses of NAC now given to children are well within serum
concentrations necessary to prevent nephrotoxicity. Carrying out a systematic review of
published NAC pharmacokinetic studies, Chen et al. [111] found steady-state plasma
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concentration to range from 0.04 to 0.9 mM and calculated NAC urinary concentration
to be 2 mM in healthy adults. They concluded that even at the lowest plasma steadystate (0.04 mM), this concentration, along with the 2 mM in the tubular lumen, is
sufficient to expose renal tubular cells to the concentration of NAC previously
demonstrated to confer protection. NAC has also been shown to prevent IFO-induced
nephrotoxicity in rats at clinically relevant doses of IFO (50 mg/kg for 5 days) [85].
These studies demonstrat the great potential for NAC to be used clinically in the
prevention of IFO-induced nephrotoxicity as evidence suggests the clinically relevant
dose used in acetaminophen overdose in children is sufficient to provide renal
protection.
A major issue in using NAC for prevention of IFO-induced nephrotoxicity is in
ensuring that this antioxidant does have an effect on the cytotoxic activity of IFO; an
issue which must be addressed before the clinical use of NAC.
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Figure 1.3 Mechanisms of NAC.
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1.6 Conclusion
Severe nephrotoxicity is a serious consideration when using IFO, especially in
the vulnerable population of children with cancer. This renal damage is owing to the
toxic metabolite produced locally in the kidney, CAA. Exerting its toxic effects through
generating oxidative stress and depletion of the cellular protection mechanism GSH, the
effects of CAA towards nephrotoxicity can be attenuated with antioxidant treatment.
Although GLY and other antioxidants have all shown to attenuate IFO-induced
nephrotoxicity in rats, NAC proves to be a clinically relevant choice, as it has a current
therapeutic use in children.

1.7 Preamble
IFO that is commonly used to treat childhood pediatric solid tumors is widely
used in combination therapies or alone. IFO has proven to be at better choice than CF in
many cases as it has a greater cure rate, greater therapeutic index and greater
antineoplastic activity. It also shows little cross-resistance and can, therefore, be used to
treat patients who do not respond to CF treatment.
In an attempt to prevent IFO-induced nephrotoxicity, research has been
conducted in recent years to clarify the mechanisms responsible for this serious adverse
effect. A major breakthrough has been realizing that local production of a toxic species,
rather than from systemic exposure, may explain the nephrotoxicity. Of great
importance in the development in this field are the investigations that support local renal
production of toxic levels of CAA and its mechanisms of toxicity to renal tubular cells,
age as relevant risk factor and the use of antioxidants in the attenuation of IFO-induced
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nephrotoxicity. Recognizing CAA as the metabolite responsible, as well as its mode of
toxicity, is beneficial in developing strategies for protection against its detrimental
effects. In knowing which cellular mechanisms have been disrupted, it becomes easier
to define strategies for mechanistic-based treatments to protect these cellular processes.
Progression of research on the use of antioxidants is supported by the knowledge that
those cellular functions that have been altered are either protected or corrected. On the
research being done with antioxidants, our opinion is that NAC shows the most
promise, as we have demonstrated it to protect renal tubular cells from CAA toxicity. It
has a current clinical use in children and is known to be safe. For a new molecule to
enter pediatric use, many years of preclinical safety studies and multimillion dollars are
needed. Such resources are not likely to become available in the hostile economic
environment today for a drug that treats relatively few children.
According to the American Physiological Society the definition of translational
research is “the transfer of knowledge gained from basic research to new and improved
methods of preventing, diagnosing, or treating disease, as well as the transfer of clinical
insights into hypotheses that can be tested and validated in the basic research
laboratory” [112]. The recent research on the use of NAC in the attenuation of IFOinduced nephrotoxicity fulfills these different perspectives of translational research. The
long known clinical presentation of IFO nephrotoxicity has been scrutinized in
preclinical studies in different experimental models including renal proximal tubular
cell lines, perfused animal kidneys, and ex vivo human and pig kidneys in the hope that
the etiology can be clarified and that this knowledge will facilitate the discovery of
possible pharmacological interventions. Considerable evidence has pointed to GSH
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depletion as a major mechanism involved in impairing endogenous protective
mechanisms and resulting in an enhanced renal insult.
The logical remedy would be then to replenish GSH levels; hence, NAC was
selected for our studies as one of its main mechanisms of action is to act as a precursor
for GSH synthesis. Because we proposed a new therapeutic usage for NAC, preclinical
studies are required to determine both efficacy and safety in early development before
any clinical trials can be undertaken. Throughout the preclinical studies, we ensured that
the studies mimicked the human condition, as much as possible, such as by using
clinically relevant drug concentrations and correlating the animal nephrotoxicity model
with the human clinical experience. These considerations are likely to enhance the
appropriate transition from preclinical discoveries to clinical development of NAC used
as a complementary therapy with IFO.
We follow the concepts of translational research, as outlined in this thesis, by
bridging the pharmacokinetic studies of NAC in the successful rat experiment with
NAC concentrations in clinical patient samples. This will help in dose selection for
future clinical trials. Overall, we have implemented different early phases of clinical
trial designs to validate a new biological therapeutic practice of NAC in children treated
with IFO. The effect of NAC on the antitumor activity of IFO both in vitro and in vivo
is also described, as the integrity of IFO therapy must be maintained during NAC
therapy, in order for it to be used a chemoprotectant. This research bridges the scientific
and operational gaps between preclinical research and early-stage clinical studies, which
provide essential benefits for developing NAC as a complementary therapeutic agent in
the near future.
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1.8 Hypothesis and objectives
Overall hypothesis: The current dose of NAC used for acetaminophen overdose will be
clinically effective for renal protection against ifosfamide-induced toxicity in children,
without interfering with IFO efficacy.
Objectives:
1- To investigate the translational pharmacokinetics of the standard NAC protocol
for acetaminophen overdose in children.
2- To investigate the possible negative effects of NAC on the antitumour efficacy
of ifosfamide in a cell model.
3- To investigate the possible negative effects of NAC on the antitumour efficacy
of ifosfamide in a rodent model.
4- To develop clinical practice recommendations for the safe and effective use of
NAC for IFO-induced nephrotoxicity.
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Chapter 2: N-acetylcysteine as a treatment against nephrotoxicity
caused by ifosfamide: Translational pharmacokinetics
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2.1 Introduction
The chemotherapeutic agent ifosfamide (IFO) is widely used for the treatment of
solid tumors in children [1,2]. Although highly effective, it is associated with high rates
of both urotoxicity and nephrotoxicity [3,4]. While severe hemorrhagic cystitis can be
effectively mitigated with the concurrent administration of 2-mercaptoenthansulphonate
(MESNA)[5,6], there is currently no preventive measure available for the serious
nephrotoxicity. The importance of such prophylactic strategy becomes evident when
considering the high rate of adverse renal effects occurring as a consequence of IFO
therapy. It has been demonstrated that as many as 30% of children treated with IFO will
have some degree of renal impairment, and 5% of children will develop full-fledged
Fanconi syndrome [7]. Although surviving their cancer, these children will continue to
suffer from renal impairment throughout their lives [8].
Ifosfamide is a pro-drug metabolized by cytochrome P450 enzymes 3A4, 3A5,
and 2B6, resulting in the production of several metabolites including the active
antineoplastic agent IFO mustard, the urotoxic metabolite acrolein, and the nephrotoxic
metabolite chloroacetaldehyde (CAA)[9-11]. The nephrotoxic CAA has been identified
by us to be produced in toxic quantities by the kidney [12-15]. The mechanism of CAA
toxicity is believed to be primarily through oxidative stress with a critical depletion of
glutathione (GSH). As a result of exposure to CAA, ATP depletion, increased lipid
peroxidation, and decreased glutathione-S-transferase activity also occur in kidney cells
[16,17]. Increases in intracellular Ca+2 and pro-inflammatory cytokines TNF-α, IL-β2,
and IL-6 [18,19], as well as decreased Na+ /K+ exchanger activity [20], have also been

50
described. As a result of this mode of toxicity, the use of an antioxidant in the
prevention of IFO-induced nephrotoxicity is biologically plausible.
N-acetylcysteine (NAC) is an antioxidant varying from the amino acid Lcysteine by one acetyl group (Figure 2.1). NAC provides protection as a GSH precursor,
increasing its synthesis and replenishing its stores. It also increases glutathione-S
transferase activity, as well as neutralizes free radicals through its nucleophilic activity
[21-23]. It has current clinical use as a topical antimucolytic agent but primarily as an
antidote for acetaminophen overdose [24,25]. Importantly, it has also been shown to
have a protective effect on the kidney in ischemia/reperfusion injury [26] and cisplatin
and cyclosporine-induced nephrotoxicity in experimental systems [27,28]. All of these
characteristics suggest NAC as a potentially effective candidate for renal protection
against IFO.
Using both in vitro and in vivo models, our group has successfully shown NAC
to exhibit a protective effect against IFO-induced renal cell damage [17] and
nephrotoxicity [16]. Attenuating both cell death and GSH depletion, NAC
demonstrated the ability to protect LLCPK-1 cells against IFO-induced damage at a
clinically relevant concentration (0.4 mM) [17]. Similarly in a rodent model, NAC
conferred protection against depleted GSH levels, diminished glutathione S-transferase
activity, elevated lipid peroxide levels, and morphological damage to the proximal
tubules and glomeruli, all seen to occur as a result of IFO therapy. NAC also diminished
the severity of tubule dysfunction with significant attenuation of elevated serum
creatinine, as well as elevated beta 2-microglobulin and magnesium urinary excretion
[16].
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However, despite being the drug of choice for acetaminophen overdose, there
are very limited data on the pharmacokinetics of NAC in children, knowledge that is of
critical importance in determining an effective therapeutic dose for preventing IFOinduced nephrotoxicity. The routine clinical use of intravenous (IV) NAC as a standard
therapy in children poisoned by acetaminophen overdose provides not only information
about its safety and efficacy in children but also an opportunity to explore its use in
children affected by acetaminophen overdose, in the context of preventing IFO-induced
nephrotoxicity. Blood samples are routinely drawn during treatment to assess
acetaminophen levels and liver function, allowing us the opportunity to characterize the
systemic exposure of NAC in children. Our objective was to compare the systemic
exposure to NAC in children treated for acetaminophen overdose (in terms of area
under the curve [AUC] over time) to the systemic exposure to NAC associated with
prevention of nephrotoxicity in our experimental rat model. This pharmacokinetic
comparison is critical in translating the systemic exposure associated with a therapeutic
effect in the rat to the needed systemic exposure in children.
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2.1 The chemical structure of NAC, varying from L-cysteine by one acetyl group.
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2.1 Materials and Methods
2.1.1 Chemicals
NAC, sodium borohydride, and butylated hydroxytoluene were purchased from
Sigma-Aldrich Canada Ltd (Oakville, Ontario, Canada). Monobromobimane was
purchased from EMD Chemicals Inc. (Gibbstown, New Jersey). IFO, 2dechloroethylifosfamide (2-DCEI), and 3-DCEI were purchased from Niomech
(Bielefeld, Germany). Deuterated 2-dechloroethylifosfamide (d6-2-DCEI) and
deuterated 3-DCEI (d4-3-DCEI) were kindly provided by Dr Susan Ludeman of Duke
University (Durham, North Carolina).
2.1.2 Pharmacokinetic study of n-acetylcysteine in rats
All experimental protocols were approved by the University of Western Ontario
Animal Care and Use Council. Male Wistar albino rats, 225 to 250 g, were purchased
from Charles River Canada (Montreal, Quebec, Canada). They were housed at a
constant temperature (22° ± 1°C) with a regular 12-hour light and dark cycle and fed a
standard rat chow and water ad libitum.
A single bolus dose of 1.2 g/kg of NAC was given intraperitoneally. Blood
samples were collected by intracardiac puncture at 5, 7.5, 10, 15, 30, and 45 minutes, as
well as 1 and 1.5 hours. Six animals were studied for each time point. Blood samples
were immediately centrifuged for 15 minutes at room temperature at 3000 rpm. Serum
samples were stored at –80°C until analysis.
2.1.3 Pharmacokinetic study of n-acetylcysteine in children
The study was approved by the Research Ethics Board (REB) at the University
of Western Ontario (Health Sciences REB No. 13625E).
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Blood samples were obtained from children and adolescents who were admitted
for acetaminophen overdose while being treated with IV NAC at the Children’s
Hospital of Western Ontario (London, Ontario) and from hospitals surrounding the
Greater Toronto Area counseled by the Ontario Poison Control Center in Toronto. All
children received the recommended dosing schedule for acetaminophen overdose at 150
mg/kg for 60 minutes, 50 mg/kg for the next 4 hours, and 100 mg/kg for another 16
hours. Blood samples were collected during routine measurements of acetaminophen
levels and liver function tests according to the management schedule at the hospital. We
received discarded blood samples from these patients after these routine measurements
were completed. The number of blood samples varied among patients as per the
discretion of their treating physicians. It is a standard practice to keep the blood samples
that have already been analyzed for 1 week in the core laboratory. We were notified of
any cases. In a parallel line of investigation, we have documented the stability of NAC
in frozen samples for more than a month.
Two pediatric case reports were also obtained describing two children receiving
IFO in combination therapy who developed acute renal failure and were subsequently
treated with NAC. Blood samples were obtained from one case for analysis of NAC and
IFO concentrations, whereas serum creatinine and glomerular filtration rate were
reported for the second case.
2.1.4 Analysis of plasma N-acetylcysteine concentrations
Total NAC concentrations were analyzed by high performance liquid
chromatography, modified from the method of Jacobsen et al. [29]. To reduce surface
tension, N-isoamyl alcohol was added to each sample, followed by sodium borohydride,
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which was used as a reducing agent for dithiol bonds. After a brief incubation,
hydrochloric acid was added to neutralize excess sodium borohydride. Thiols in the
samples were derivatized with monobromobimane, a fluorescent labeling agent. To
prevent any large proteins from eluting through the chromatography column, perchloric
acid was used to precipitate the proteins, after which the samples were centrifuged at
9000 g for 5 minutes. To neutralize the acid, the sample pH was raised to 3.5 by adding
a solution of 2 M citrate in 10 M sodium hydroxide. The samples were centrifuged at
9000 g for an additional 3 minutes. One hundred microliters of the supernatant of each
sample were transferred into a glass insert, and 5 uL was injected into a 15 cm x 3.9
mm, 5 u Novapak C18 column maintained at 40°C in a Hewlett Packard 1090 LC. The
mobile phase (Pump A: 4% acetonitrile/ 25 mM ammonium formate buffer, pH = 3.8
with formic acid; pump B: 70% acetonitrile/10 mM KH2 PO4 buffer, pH = 3.0 with
phosphoric acid) was run at 0.5 mL/min, and the eluent was detected by a Waters 474
scanning fluorescence detector with the excitation set to 390 nm and the emission set at
480 nm. The accuracy and precision of the assay were 1.3% and 2.0%, respectively.
2.1.5 Pharmacokinetic calculations
The AUC for plasma concentration-time curve was calculated according to the
trapezoidal rule during the period of sample collection, where:

AUCc0–c1 = C0 + C1/2 x (T1 - T0).

A sum of AUC from each time interval gave the total AUC. Extrapolation of
AUC to infinity was made by AUCt – ∞ = Ct/Kel, where Ct is the last time point the
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sample was measured and Kel is the elimination rate constant calculated from the
descending slope of the plasma concentration curve. The final AUC in children is the
sum of AUC from the definite area plus the residual area. The final AUC in rats is the
sum of AUC from the definite area plus the residual area, multiplied by 6, as the
therapeutically effective model consisted of 6 daily doses of 1.2 g/kg.
2.1.6 Analysis of ifosfamide plasma concentrations
Plasma samples were analyzed using our previously published method by
Aleksa et al. [30]. All analyses were carried out under ambient temperatures. Briefly,
100 μL of plasma was used for analysis, and 100 μL blank plasma was spiked with IFO
(5-100 ng/mL) for the standard curve. All samples were spiked with 10 μL of internal
standard mix (10 μM trofosfamide). Methylene chloride was added for liquid-liquid
extraction. First, we vortexed the samples for 45 seconds, following which they were
centrifuged for 10 minutes at 4000 rpm at 4°C. The top aqueous layer was removed and
using a stream of nitrogen gas, the organic layer was dried. Reconstitution of the
samples was done using 30 μL of 10 mM ammonium acetate (pH, 7.0), and 5 μL was
injected into the LC/ MS/MS for analysis.
The samples were analyzed on an Agilent 1100 Series high-performance
liquid chromatography (Agilent Technologies, Mississauga, Ontario) equipped with an
Agilent 1100 Series binary pump. The separation of analytes was done with a CHIRALAGP column (150 x 4.0 mm, 5 μM, Chrom Tech, Apple Valley, Minnesota) using 10
mM ammonium acetate in water (pH, 7.00) (A) and 30 mM ammonium acetate in water
(pH 4.00) (B) with the following gradient: time 0.0 minutes, A 5 100%, flow 400
mL/min; time 4.5 minutes, A 5 50%, flow 400 mL/min; time 7.10 minutes, A 5 100%,
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flow 600 mL/minute. Introduction of the samples to the chromatographic system was
completed with an Agilent 1100 Series Autosampler (Agilent Technologies). An LCMS/MS API4000 Triple-Quadrupole was used for mass spectrometric detection
(Applied Biosystems, MDS SCIEX, Foster City, California). LC-MS/MS API4000
Triple-Quadrupole was set with an API turbo ion spray ionization (PIS) source and
functioned in positive ion mode. Analytes were quantified using multiple reactions
monitored, with transitions monitored for IFO being m/z 261.1 to 154. Voltage of the
ion spray was set at 5.5 kV, with source temperature was kept constant at 500°C. Data
acquisition was performed using MDS-SCIEX Analyst software (version 1.4).

2.3 Results
2.3.1 N-acetylcysteine pharmacokinetics in a rodent model
The mean systemic exposure of a 1.2 g/kg intraperitoneal dose of NAC in rats
was 3.12 mM·h (Figure 2.2). In our rat model, in which NAC therapy conferred
protection against IFO-induced nephrotoxicity, we gave NAC at 1.2 g/kg
intraperitoneally daily for 6 days [16]. Therefore, the total mean systemic exposure of
the rat model demonstrating therapeutic efficacy was 18.72 mM·h. The lower and upper
limits of systemic exposure in the rat model were 9.92 and 30.02 mM·h, respectively
(Table 2.1).
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Figure 2.2 The systemic exposure of NAC in a rat model receiving a 1.2 g/kg
intraperitoneal dose of NAC (n = 3 for each time point). AUC is 3.12 mM·h, where the
dotted line represents the residual area calculated. Total systemic exposure is 18.72
mM·h, as 6 doses were given.
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Table 2.1 A comparison of mean, higher and lowest systemic exposures of NAC
between children/adolescents and the rat model.
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Highest
Systemic
Exposure,
mM·h

Lowest
Systemic
Exposure,
mM·h

14.48

32.96

6.22

18.72

30.02

9.92

Mean Systemic
Exposure, mM·h
Children/
adolescents
Rat Model
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2.3.2 N-acetylcysteine pharmacokinetics in children and adolescents
Discarded blood samples were collected from 16 children and adolescents
treated for acetaminophen overdose. Six children were excluded from AUC calculations
either because there was no information on the time blood samples were drawn or
because they were not given the standard 21-hour NAC IV therapy. Ten of the 16
children were given the standard NAC protocol for acetaminophen overdose and had a
mean systemic exposure of 14.48 mM·h (Table 2.2). The lowest systemic exposure seen
in children was 6.22 mM·h, and the highest was 32.96 mM·h (Figure 2.3 and Table 2.1).
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Table 2.2 AUC calculations for patients receiving the standard NAC protocol for
acetaminophen overdose.
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Subject
1
2
3
4
7
8
9
11
13
14
Mean

Systemic Exposure of Children/Adolescents Treated
With the Standard NAC Protocol for Acetaminophen
Overdose (mM·Hr)
32.96
20.57
17.58
8.01
10.93
6.22
7.46
13.27
16.95
10.38
14.48 ± 7.62
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Figure 2.3 The systemic exposure of NAC in a child (subject 1) receiving the standard
NAC IV protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100 mg/kg for
16 hours. Area under the curve is 32.96 mM·h, where the dotted line represents the
residual area calculated.
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2.4 Case reports
2.4.1 Case report 1
A 10-year-old girl was hospitalized at the University Children’s Hospital
Belgrade, Serbia, with primitive neuroectodermal tumor and acute renal failure. Her
tumor was aggressive with liver metastases. She underwent surgery; however, some
tumor masses could not be removed. The patient received the following protocol:

Day 1. Ifosfamide 3 g/m2, vincristine 1.5 mg/m2, dactinomycin 1.5 mg/m2, and
MESNA and NAC (IV dosage for acetaminophen overdose: 150 mg/kg loading
dose over 60 minutes of continuous infusion, 50 mg/kg over 4 hours, 100 mg/kg
over 16 hours). She underwent dialysis after 24 hours. There were no adverse
reactions apart from vomiting.
Day 2. Ifosfamide 3g/m2 and MESNA and NAC (IV dosage for acetaminophen
overdose). She underwent dialysis after 19 hours. There were no adverse
reactions.
Day 3. IFO 3 g/m2 and MESNA without NAC. After 12 hours, face fasciculations
appeared, and electroencephalogram confirmed encephalopathy, so she
underwent dialysis after 15 hours. After continuous dialysis, the patient
recovered. She also received ondansetron, meropenem, furosemide, and
morphine as needed. After the first dose, she exhibited unexpected diuresis of
200 mL/kg, whereas after the third dose the diuresis was completely recovered.

She showed all signs of tumor lysis. She did not show either clinical or
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laboratory evidence of renal failure. The child’s systemic exposure to NAC was 21.68
mM·h after the first NAC dose and 14.92 mM·h after the second, resulting in a total
systemic exposure of 36.60 mM·h (Figure 2.4). Ifosfamide exposure was also calculated
(Figure 2.5).
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Figure 2.4 The systemic exposure of NAC in patient from case report 1, where the
patient received 2 doses of the standard NAC IV protocol, 150 mg/kg for 60 minutes, 50
mg/kg for 4 hours, and 100 mg/kg for 16 hours, during her IFO therapy. AUC is 36.60
mM·h.
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Figure 2.5 Total systemic exposure of IFO in patient from case 1, where the patient
received 3 doses of 3 g/m2.
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2.4.2 Case report 2
A 15-year-old Hispanic male was admitted to the hospital for chemotherapy for
abdominal recurrence of mixed germ cell testicular tumor. He was diagnosed with the
primary tumor 8 months earlier and underwent right orchiectomy and chemotherapy per
protocol ACTZ0132, which included cisplatin, etoposide, and bleomycin. His serum
creatinine was elevated after the first chemotherapeutic cycle and remained in the
higher ranges of 1.2 to 1.6 mg/dL throughout. His serum alpha fetoprotein and beta
HCG levels showed a rise 7 months after initial induction chemotherapy; he was
reassessed and was found to have an abdominal relapse on computed tomography. On
the day of admission, his serum creatinine was 1.23 mg/dL, sodium 137 mmol/L,
potassium 4.1 mmol/L, magnesium 1.8 mg/dL, and alpha fetoprotein 1204.7 ng/mL.
The next day, after hydration with fluids, the patient received the following protocol:

Day 1. Paclitaxel 257 mg, carboplatin 653 mg, IFO 3400 mg, and MESNA 684 mg.
Days 2-5 IFO 3420 mg and MESNA 684 mg, along with appropriate prehydration
and posthydration. Creatinine started rising by day 2 and steadily increased up to
2.06 mg/dL by day 7, along with decrease in urinary output (Figure 2.6).
Day 7-10. Oral NAC 600 mg BID. NAC was discontinued on day 11.

After reaching a peak of 2.25 mg/dL on day 8, serum creatinine showed a steady
decrease to 1.12 mg/dL on the day of discharge, which was day 15. The urine output
also showed similar improvement on initiation of NAC. His serum magnesium
throughout this period stayed between 1.7 and 1.9 mg/dL.
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Figure 2.6 Serum creatinine levels of patient from case report 2 in response to NAC
therapy.
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2.5 Discussion
Nephrotoxicity is a serious adverse effect of IFO therapy, affecting 30% of
children treated [7]. As this renal toxicity is likely mediated primarily by oxidative
stress, the use of NAC, an antioxidant, as a prophylactic treatment for its prevention has
been proposed. This study is one of the first to examine the pharmacokinetics of NAC
in the pediatric age group. The goal of this study was to determine whether NAC
plasma concentrations (in terms of AUC) in patients are producing adquate systemic
exposure compared to our experimental rodent model. Our results show that
therapeutically effective levels of NAC in preventing IFO-induced nephrotoxicity in a
rat model are comparable to systemic exposure in children being treated with the 21hour IV NAC protocol for acetaminophen overdose. Mean systemic exposure in the rat
model was 18.72 mM·h, compared to 14.48 mM·h in children. The distribution of
systemic exposures in the rat model and in children was also similar, with the lowest
exposures being 9.92 mM·h and 6.22 mM·h in the rat model and in children,
respectively. Similarly, the highest range systemic exposure seen in the rat model and in
children was 30.02 mM·h and 32.96 mM·h, respectively. These results suggest that the
current therapy of NAC for pediatric acetaminophen overdose shows promise in
providing renal protection for children who are on IFO therapy. We have corroborated
these results with two cases of IFO-induced nephrotoxicity, where NAC appeared to
mitigate nephrotoxicity. Measurement of NAC in case 1 further supports the level of
systemic exposure to NAC needed to protect against nephrotoxicity. Out of these two
cases described by us, one child was dialyzed, and hence in said case clinical
improvement may not be directly related to NAC. A randomized control trial is needed

78
to quantify the efficacy of NAC for IFO-induced nephrotoxicity.
Of importance, in comparing the systemic exposure of the rats and children, the
systemic exposure in the pediatric acetaminophen overdose cases might have been an
underestimate. Blood obtained for calculating the AUC of NAC in children was based
on discarded samples; therefore, we were limited in our ability to obtain a specific
preset number of samples or samples at predetermined time points. On AUC
calculation, we had to assume that the highest NAC concentration measured was the
peak concentration, although blood levels could potentially still be increasing; hence,
our calculated AUC may be an underestimation of the actual systemic exposure. In
addition, the difference in length of treatment between the rat model and the children
has to be considered. Our therapeutically effective rat model was treated with NAC for
6 days, whereas children treated for acetaminophen overdose were treated only once for
a 21-hour period. Our goal was to conclude if the 21-hour IV protocol provides an
overall systemic exposure equivalent to the rat model, in terms of total body exposure to
NAC not length of exposure. However, we may also consider that children receiving a
similar number of NAC treatments as the rat model would achieve a systemic exposure
that well exceeds the AUCs found to be therapeutically effective in our rodent model.
Moreover, there are descriptions of NAC protocols for paediatric acetaminophen
toxicity that extend several days.
Although several antioxidants, including resveratrol [19], melatonin [20],
taurine [31], glycine [32], L-histidinol [33], and thymoquinone [34], have also been
shown to prevent IFO-induced nephrotoxicity in rat models, in the clinical setting, NAC
is currently the only one approved for and commonly used in children. Although the
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antioxidants melatonin and resveratrol are being assessed for use in children for sleep
disorders [35,36] and obesity prevention [37], little to no information on their safety in
children is available, making their use for an alternative indication, such as renal
protection during IFO therapy, years from being realized. NAC is widely used clinically
in both children and adults as treatment for acetaminophen overdose. Acetaminophen is
the most regularly used pain-relieving agent worldwide [38,39] and is the most common
cause of both intentional and unintentional drug overdoses. In the United States, more
than 30 000 hospitalizations occur annually involving acetaminophen overdose [40].
Because NAC is used as an antidote under these circumstances, this provides a wealth
of information on the safety and efficacy of NAC in children. This information is
critical when assessing the use of NAC for an alternative indication in children, in this
case renal protective strategies when using nephrotoxic agent, and from a time
perspective makes NAC the most relevant choice.
The most commonly used NAC protocol for acetaminophen overdose is the 21hour IV protocol, which has been used for decades by Canada, Europe, and Australia
and since 2004 by the United States. The 21-hour IV NAC protocol includes a 150
mg/kg loading dose infused for 60 minutes and 2 maintenance IV doses: 50 mg/kg for 4
hours and 100 mg/kg for 16 hours [41,42]. As this is the standard therapy associated
with acetaminophen overdose in Canada, the systemic exposures of NAC measured in
our patients adequately represent this course of therapy. Overall, it provides a total of
300 mg/kg of NAC over 21 hours (Table 2.3). Before 2004 in the United States, a 72hour oral protocol for NAC was the standard therapy in cases of acetaminophen
overdose [42]. This protocol includes a 140 mg/kg loading dose, followed by seventeen
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70 mg/kg maintenance doses every 4 hours [43]. It allows a total of 1330 mg/kg over
72 hours or 53.2 to 133 mg/kg systemically over 72 hours in consideration of the oral
bioavailability of NAC, found to range from 4% to 10% [44]. Alternatively, a 36-hour
oral protocol and 48-hour IV protocol have also been described [45,46]. Although the
36-hour protocol is a truncated version of the 72-hour oral protocol, the 48-hour IV
protocol involves a 140 mg/kg loading dose and twelve 70 mg/kg maintenance doses
every 4 hours, providing of total of 980 mg/kg over 48 hours. When compared in terms
of safety and efficacy in treating acetaminophen overdose, all 3 protocols, the 21-hour
IV, 48-hour IV, and 72-hour oral protocols, were found to be equivalent, with the 48hour and 72-hour protocols appearing superior in later treated patients. In the context of
this translational research, a 2- to 3-fold higher systemic exposure to NAC than the one
used by us has also been shown to be safe in children. This may be of importance if the
pharmacodynamics of NAC in IFO-induced nephrotoxicity necessitates more NAC than
was effective in the rat model.
In terms of safety, both oral NAC and IV NAC have been shown to be safe with
an uncommon incidence of adverse events [47]. Nausea and vomiting are common side
effects associated with administration of both oral and IV NAC [48,49]. Anaphylactoid
reactions are more commonly associated with IV NAC, as opposed to oral NAC,
occurring at a rate of 0% to 48% [47]. This is thought to be attributed to the infusion
rate; however, most cases are minor and easily manageable. Under most circumstances,
NAC can be resumed and the treatment protocol completed. Life-threatening or serious
events have an incidence of less than 5% [47,50-53]. One report of an anaphylactoid
reaction occurring during oral NAC treatment has been documented, although after
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treatment of symptoms the patient resumed and completed the NAC protocol [54].
To the best of our knowledge, this is the first attempt to determine NAC
pharmacokinetics in a pediatric age group. The conventional dosage schedule used in
the 21-hour IV NAC treatment for acetaminophen overdose in children produced
systemic exposure comparable to that of our rat model associated with therapeutic effect
in nephrotoxicity prevention. Similarly, with NAC protocols that provide an overall
higher dose existing, the ability to achieve systemic exposures closer to or greater than
our successfully treated rodent model becomes possible, even further supporting the use
of NAC for this alternative indication. We describe here the first two case reports of
NAC given during IFO therapy, associated with successful prevention of acute renal
toxicity. Case report 1 presents the successful use of the 21-hour IV protocol, and case 2
shows the successful use of oral NAC (600 mg orally, twice per day), despite its low
oral bioavailability (4%-10%). These cases suggest not only that the current NAC
protocol used for acetaminophen overdose, for which pharmacokinetics in children was
assessed in this study, will be successful as a prophylactic treatment for IFO-induced
nephrotoxicity but that other formulations and doses may also provide adequate
protection. These cases also corroborate the safe and effective use of NAC in children,
as reported by previous studies. Together with our recent data on the lack of effect of
NAC on IFO efficacy, described later in this thesis, the present study, as well as the case
reports, further strengthens the choice of NAC as a therapeutic option to prevent IFO
nephrotoxicity in children. Our results support a randomized control trial to quantify the
effects of NAC on IFO nephrotoxicity. Based on the preliminary clinical results
available to us, it is reasonable to consider NAC treatment when the first signs of IFO-
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induced nephrotoxicity emerge. Furthermore, our study looks at the systemic exposure
in children treated only with the standard 21-hour IV protocol; the existence of
protocols varying in route of administration, overall dose, and length affords future
opportunity to assess the utility of such protocols.
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Table 2.3 A comparison of total systemic dose received (mg/kg) by each NAC protocol
described in the literature.
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Protocol
Dose

Loading Dose
mg/kg

72-hour oral
48-hour intravenous
36-hour oral
21-hour oral

140
140
140
150

Maintenance Dose
mg/kg
70 every 4 hours x 17
70 every 4 hours x 12
70 every 4 hours x 9
50 for 4 hours followed by
100 for 16 hours

Total Systemic
mg/kg
53.2-133
980
30.8-77
300

Oral bioavailability (4-10%) is accounted for in total systemic dose for oral
protocols
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efficacy: in vitro
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3.1 Introduction
With its use today in many pediatric and adult cancers including
rhabdomyosarcoma, osteosarcoma, neuroblastoma, Ewing’s sarcoma, leukemia and
non-hodgkins lymphoma, ifosfamide (IFO) is an important chemotherapeutic agent in a
large repertoire of available antineoplastic drugs [1-5]. IFO was developed in the 1970s
as an analogue of the nitrogen mustard cyclophosphamide [6]. It is a DNA alkylating
agent, causing cytotoxicity through its ability to form both inter- and intra-DNA strand
cross links, preventing cell replication and in time leading to cell death [7]. Despite its
high therapeutic index, rather rare cross-resistance, and treatment success for certain
cancers that do not respond to cyclophosphamide [8, 9], IFO use does not come without
serious health risks. Adverse effects common to many cancer drugs including
gastrointestinal toxicity, myelosuppression, and neurotoxicity occur with IFO therapy,
along with two dose limiting late effects: urotoxicity and nephrotoxicity [10-13].
The use of IFO was first limited due to extremely frequent and severe bladder
toxicity [14]. This is now successfully treated with sodium 2-mercaptoethanosulphonate
(MESNA), routinely given in conjunction with IFO, in the amount of 40% (if given
orally) or 20% (if given intravenously), of the ifosfamide dose. Following successful
use of this chemoprotectant, treatment protocols were able to include both higher and
more frequent IFO dose schedules, leading to the awareness of a new dose limiting
toxicity, that of the kidney [2, 15, 16].
Kidney toxicity associated with IFO is an age-dependent issue, with 30% of
children who are treated with IFO developing some form of nephrotoxicity [17-19]. The
nephrotoxicity can vary from minor tubular dysfunctions to full blown proximal tubular
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dysfunction in the form for Fanconi syndrome, which affects 5% of children treated
[20-22]. Glomerular toxicity may also be present in as many as 30% of children [11].
These dysfunctions may result in disorders such as hypophosphatemic rickets, renal
tubular acidosis and chronic renal failure. Severely impacting the quality of life of those
affected, their toxicity may lead to the need for lifelong supplementations, renal
dialysis, renal transplant, or in some case death [11, 20-24].
It is not IFO itself that is responsible for urotoxicity and nephrotoxicity, rather
products of its metabolism, acrolein and chloroacetaldehyde (CAA) respectively [2527]. Metabolized by cytochrome P450's 3A4, 3A5 and 2B6, IFO is a pro-drug requiring
biotransformation to produce the active antineoplastic agent, ifosfamide mustard (IFM).
This occurs through ring hydroxylation, resulting in both IFM and acrolein. 50% of IFO
is metabolized through this pathway, while the remainder undergoes side chain
oxidation, producing the metabolites 2- or 3- dechloethylifosfamide with equal amounts
of CAA [28-30]. CAA is currently understood to be responsible for nephrotoxicity
associated with IFO. Early studies demonstrated that systemic exposure of CAA, as
measured by area under the curve, does not have a positive correlation with degree of
nephrotoxicity. Those having a higher AUC showed a lesser degree of nephrotoxicity
[31]. However, more recent findings suggest that renal, not hepatic metabolism of IFO
is responsible for the production of renal toxic quantities of IFO. These studies
demonstrated that the kidney not only possess the CYP P450s required for metabolism,
but that they kidney is capable of producing quantities shown to be nephrotoxic [27, 3234].
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CAA functions as a nephrotoxin primarily through the generation of oxidative
stress. Exposure to CAA results in several insults including increases in ROS, depletion
of ATP, increases in intracellular calcium, increases in intracellular sodium, release of
pro-inflammatory cytokines, and importantly, depletion of GSH [35-43]. These
mechanisms of toxicity, resulting in increased oxidative stress, aid in defining a clear
direction for protective strategies: antioxidants.
As MESNA, an antioxidant, is currently used alongside IFO, its renal protective
effects have been assessed. While in vitro work has successfully shown MESNA will
also protect against IFO-induced nephrotoxicity, rodent studies bring to light that this is
not the case in vivo [44]. MESNA rapidly auto-oxidizes to diMESNA in the blood and
is then reduced back to its free thiol form in kidney; in its reduced state, it is able to
protect the bladder epithelium. Reduction back to MESNA occurs at the expense of
renal glutathione (GSH), which becomes oxidized and requires its own reduction before
it can again protect cells against oxidative damage [45]. Exhaustion of GSH stores
within the kidney, an organ that already has lower GSH levels than the liver, may
predispose the kidney to damage from oxidative insult, which as discussed above, is the
primary mechanism of IFO toxicity.
N-acetylcysteine, however, in an antioxidant that has shown great promise
protecting against IFO kidney toxicity. NAC is an effective renal protectant in both
proximal tubule cell and rodent models, using clinically relevant concentrations [46-48].
And while several other antioxidants have also shown protective properties against IFOinduced nephrotoxicity in animal models [40, 41, 49-52], NAC is the most promising
choice. First, like the other antioxidants, NAC is a nucleophile with ROS-scavenging
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properties. However unlike the others, NAC is also a precursor to GSH synthesis [5355]. This becomes important when evaluating the significant reduction of GSH in the
kidney, caused by IFO. Second, NAC is currently the only antioxidant to have shown
protection, which is used clinically. As an antidote for acetaminophen overdose, NAC is
currently both effectively and safely used in children for hepatic protection against
oxidative damage [56]. Furthermore, the 21-hour IV dose used in acetaminophen
overdose, as discussed earlier in this thesis, should also be sufficient to provide renal
protection [57].
However, despite the growing support in favor of the effective use of NAC to
prevent IFO-induced nephrotoxicity, it must first be demonstrated that NAC does not
interfere with the anticancer effects of IFO. The purpose of this study is to evaluate the
effects NAC on IFM in two relevant cancer cell lines. The addition of MESNA was also
included to assess if the NAC + MESNA combination has any effect on IFM efficacy.

3.2 Materials and Methods
3.2.1 Reagents
MESNA, NAC and the tetrazolium salt MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) were bought from Sigma–Aldrich Canada Ltd. (Oakville,
ON., Canada); IFO from Baxter Oncology GmbH and Baxter Corporation, HallenWestfalen, Germany) and IFM from Eno Research and Development (Research
Triangle Park, Durham, N.C., USA).
3.2.2 Cell lines and cell cultures
Two different pediatric cancer cell lines that are sensitive to IFO treatment were
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used: neuroblastoma SK-N-BE(2) (ATCC No. CRL-2271, Cedarlane Laboratories Inc.,
Burlington, ON., Canada) and rhabdomyosarcoma RD114-B (ATCC No. CRL-7763,
Cedarlane Laboratories Inc.). Both neuroblastoma cells and rhabdomyosarcoma cells
were cultured as subconfluent monolayers at 37 °C in a humidified atmosphere with 5%
CO2. Neuroblastoma cells were cultured in a 1:1 mixture of Eagle’s minimum essential
medium and F12 medium with 10% fetal bovine serum (Invitrogen, Burlington, ON.,
Canada) and 1% penicillin–streptomycin (Invitrogen). Rhabdomyosarcoma cells were
cultured in Dulbecco’s modified eagle’s medium with 10% fetal bovine serum, 1%
penicillin–streptomycin, and 2 mmol/L L-glutamine (Invitrogen). Both cell lines were
supplied with fresh media and subcultured 2–3 times each week by trypsinization with
0.25% trypsin with EDTA.
3.2.3 Experimental Design
First, a dose response curve for both IFO and IFM was established by incubating
both rhabdomyosarcoma and neuroblastoma for 24 hours at various concentrations,
followed by MTT assay at 24 hours.
Next, the different drug treatment groups were added to each well of the
microplate on day one. Both pretreatment and concurrent regimens were employed to
each treatment group. Pretreatment groups were treated with a 4-hour incubation of
NAC alone on day 0. The treatment groups were as follows:
1) 100 uM IFM alone. Concentration as informed by previous experiment
2) 0.4 mM NAC + 100 uM IFM
3) 0.3 mM MESNA + 100 uM IFM
4) 0.4 mM NAC + 0.3 mM MESNA + 100 uM IFM
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Cells were incubated for 4 hours, following which drug containing media was
removed and fresh medium was added. Cells were cultivated for 4 days, with MTT
being added on day 5.
Concentrations of both NAC and MESNA are clinically relevant, with 0.4 mM
of NAC being the estimated steady state concentration in children [46] and 0.3 mM
being the minimum urinary concentration of MESNA in children and adolescents [13].
3.2.4 MTT assay
Cell viability was measured using the MTT assay as described by Mosmann
[58]. Cells were incubated in 96-well plates containing either 1.5 x 104 cells per 100 μL
adherent rhabdomyosarcoma cells or 4 x 104 cells per 100 μL mixture of suspension and
adherent neuroblastoma cells. Depending on the treatment group, a drug or combination
of drug solution was added to each well of the microplate, and incubated for the
appropriate amount of time. On the specified day, as informed by the treatment
regimen, 10 uL of sterile MTT solution (5mg/mL MTT) in phosphate buffered saline
was added to each well, followed by incubation at 37°C for 2.5 hours. The reaction was
stopped with 100 uL of acidic isopropanol solution. Difference in absorbance values at
570 nm and 690 nm were determined using Tecan Safire2TM microplate reader (Durham,
NC).
3.3.5 Statistical analysis
Studies were replicated at least 3 times or more. Comparison of treatment
groups was done using a one-way analysis of variance (ANOVA) followed by the
Student-Newman-Keuls post hoc test. Values are presented as means±standard error.
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3.3 Results
3.3.1 Concentration dependant effects of ifosfamide and ifosfamide mustard
We first determined the effect of the parent compound IFO and the
pharmacologically active metabolite IFM on cell growth of RD114-B and SK-N-BE(2)
cell lines, two relevant pediatric cancers (Figure 3.1 & 3.2). In either cell lines, the
parent drug ifosfamide did not result in decreased cell growth until non-clinically
relevant concentration of 5 mM. On the other hand, IFM produced a dose-dependent
decrease in cell viability at low micromolar concentrations in both cell lines. At 100
μmol/L IFM more than 50% cell death was observed (n=3).
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Figure 3.1 The effect of IFO and IFM on RH cell growth, expressed as a percentage of
control. (*, p < 0.05 **, p < 0.01).
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Figure 3.2 The effect of IFO and IFM on NR cell growth, expressed as a percentage of
control. (**, p < 0.01).
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3.3.2 The effect of pre-treatment with n-acetylcysteine on tumor cells treated with
ifosfamide mustard
A single concentration of each metabolite was used for the combined treatments
that included NAC, MESNA, and NAC plus MESNA. In both cancer cell lines, as
anticipated, 100 μmol/L of the antineoplastic metabolite IFM significantly decreased
cellular viability (p < 0.001) (Figure 3.3 & 3.4). When NAC alone was given together
with IFM, there were no significant changes in viability as compared with the effect of
IFM treatment alone. MESNA has been routinely used as part of concurrent treatment
with ifosfamide. In accordance with clinical experience, MESNA did not significantly
alter cell viability when it was given concurrently with IFM. When both thiols MESNA
and NAC were given together with IFM, there was no further increase in the viability of
these cancer cells (n=5).
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Figure 3.3 The effect of pre-treatment with NAC + IFM on RH cell growth, expressed
as a percentage of control. (***, p < 0.001). NAC and N, n-acetylcysteine; MES and M,
sodium 2 mercaptoethanesulfonate.
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Figure 3.4 The effect of pre-treatment with NAC + IFM on NR cell growth, expressed
as a percentage of control. (***, p < 0.001). NAC and N, n-acetylcysteine; MES and M,
sodium 2-mercaptoethanesulfonate.
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3.3.3 Effect of concurrent treatment of n-acetylcysteine on tumor cells treated with
ifosfamide mustard
We compared the 2 different treatment regimens to determine whether
pretreatment of the cancer cells with NAC would produce a result different from that
achieved by concurrently treating them with NAC and the metabolites. As most patients
with malignancies appear to have markedly lower plasma GSH levels than patients in
good health [59], addition of a modulating agent like NAC, which has the ability to
increase intracellular and plasma GSH [53], may increase the endogenous protective
capacity to deal with reactive toxic metabolites. As shown in both cancer cell lines, the
different types of combined treatments with IFM produced no significant changes in
cellular viability as compared with the effect of IFM treatment alone (n=4) (Figure 3.5
& 3.6).
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Figure 3.5 The effect of concurrent NAC + IFM on RH cell growth, expressed as a
percentage of control. (***, p < 0.001). NAC and N, n-acetylcysteine; MES and M,
sodium 2-mercaptoethanesulfonate.
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Figure 3.6 The effect of concurrent NAC + IFM on RH cell growth, expressed as a
percentage of controls. (***, p < 0.001.) NAC and N, n-acetylcysteine; MES and M,
sodium 2-mercaptoethanesulfonate.
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3.4 Discussion
With the 5 year survival rate for childhood cancer climbing above 80%, and
over 270 000 childhood cancer survivors in the United States, more focused efforts to
prevent late effects of chemotherapy are required [60, 61]. Two thirds of pediatric
cancer survivors will develop health conditions as a result of their cancer therapy with
one third dealing with conditions that are either severe or life-threatening [62]. These
debilitating conditions hinder the quality of life of these survivors, and while they may
be able to live a life that is cancer free, their health continues to suffer.
Our group has extensively studied the use of NAC as a chemoprotectant against
IFO-induced nephrotoxicity. We have previously demonstrated that NAC will protect
against IFO cytotoxicity and depleted GSH in LLCPK-1, a porcine renal proximal
tubule cell line, at concentrations shown to be therapeutically relevant in children based
on pharmacokinetic modeling [46, 47]. NAC also protects against a rodent model of
IFO-induced nephrotoxicity, in which depleted glutathione, impaired glutathione Stransferase and lipid peroxidation were all observed and protected against with NAC.
Also observed was increased serum creatinine, and urinary loss of β2 microglobulin and
magnesium, as well as loss of nephron morphological integrity, again prevented with
treatment of NAC [48]. However, despite the evidence in support of NAC to prevent the
nephrotoxicity caused by IFO, its use has not been adopted clinically. This is most
likely owing to the lack of information on the potential interaction between NAC and
the chemotherapeutic integrity of IFO. While some studies have suggested thiol
chemoprotectants such as NAC do not block the antitumor efficacy of antineoplastic
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drugs during chemotherapy [63-65]), others suggest NAC may protect against the
cytotoxicity resulting from some chemotherapy treatments.
NAC has been used in a number of in vitro experiments as a way of assessing
potential chemotherapeutic agents’ mechanisms of antitumor activity, including studies
with MSFTZ, a flavanone derivative [66]; isoobtusilactone A from Cinnamomum
kotoense [67]; aclarubicin [68]; sanguinarine [69]); asteriscunolide [70]; and [71].
These compounds possess antitumor activity in a variety of cell lines, through a variety
of mechanisms. In these studies, NAC demonstrated the ability to protect against
mechanisms such as mitochondrial dysfunction [66, 68], Bcl-2/Bax modulation [66],
apoptosis [66, 68, 69], increased levels of reactive oxygen [65, 68, 70, 71], caspase
activation [69], reduced ERK phosphorylation [71], and ultimately cell cytotoxicity.
The ability of NAC to protect through one or more of these mechanisms leads to the
common conclusion that reactive oxygen species played a pivotal role in the antitumor
activity of the compound being tested [66-71]. Despite this, only one study assessing
NAC’s antitumor activity in consideration of its role as a chemoprotectant found
negative results. Wu et al. [65] showed that NAC blocks the cytotoxic effects of
cisplatin when given concurrently with or up to 2 h after treatment. However, the same
study suggested that the timing of NAC administration might potentially be adjusted in
order for it to act as a chemoprotectant without affecting antitumor activity. Similar
conclusions were reported by Muldoon et al. [63] and Neuwelt et al. [64], who
demonstrated that separation of spatial and temporal administration of chemoprotectants
and chemotherapeutic drugs can protect the integrity of both treatments. Also of
significance is a study by Heaney et al. [73], who report that NAC does not affect the
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cytotoxicity of the antineoplastic drugs vincristine, doxorubicin, methotrexate, and
imatinib, although it did attenuate cytotoxicity caused by cisplatin. Of importance, in
our study we did not measure the production of reactive oxygen species, as it is well
established that the majority of cell death caused by IFM is due to apoptosis, with some
cells dying of necrosis (Becker et al. 2002; Zhang et al. 2005). Previous studies by our
group and others have established that NAC does in fact decrease oxidative stress [48].
However, the efficacy of vincristine, doxorubicin, methotrexate, and imatinib, which
also elicit their antitumor effects through apoptosis, was not negatively affected by
NAC [74-77]. For this reason we focused our paper only on the cell death caused by
IFM and the possible effects of NAC on its cytotoxicity.
Of similar interest are reports that antioxidants may act synergistically when
added to chemotherapy treatments, resulting in greater antitumor activity than with
treatment with the antineoplastic drug alone. Thymoquinone potentiates IFO and
cisplatin antitumor activity [50], while melatonin acts synergistically with IFO and
vincristine tumor kill [78], both of which have been shown in animal models. While
similar studies have not been carried out with NAC and IFO, Gao et al. [79]
demonstrated that NAC does have antitumorigenic effects. NAC demonstrated
antitumor effects in 3 tumorigenic models in vivo through increased degradation of a
protein involved in tumorigenic pathways, HIF-1, which regulates genes involved in
angiogenesis, mitochondrial function, and glycolysis.
While there are conflicting data on the role of NAC and its antitumor effects,
most of the data looking at NAC as a chemoprotectant suggest that it will not interfere
with IFO activity. Therefore, the aim of this study was to determine if NAC has a
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negative effect on the ability of IFM, to kill cancer cells. We looked at two relevant
cancer cell lines, in which IFO is often included for their treatment. Our results
demonstrated that NAC does not affect the tumor kill of IFM in either neuroblastoma or
rhabodmyosarcoma cells lines. This was true for both concurrent and pretreatments,
either with NAC alone or NAC in combination with MESNA.
It is important to note that IFM rather than the parent compound IFO was used
in these experiments. IFM is in fact the active antineoplastic form of IFO. It is cyctoxic
through actions as cell cycle non-specific DNA alkylating agent. IFM has two highly
reactive alkyl groups, which are both able to from covalent bonds with 7-nitrogen of
purine bases in DNA. With two moieties capable of forming these covalent bonds, both
intra- and inter- DNA strand cross links are possible, resulting in an impaired ability of
the cell to undergo DNA relocation, signaling cell death [80, 81]. Rapidly dividing
cells, such as cancer cells, are most affected by this type of agent.
The formation of IFM occurs through ring hydroxylation of IFO. Enzymatic
conversion of IFO occurs to form 4-hydroxyIFO, which then spontaneously converts to
aldo-IFO, which may also exist in its tautomeric form carboxyl-IFO. Aldo-IFO then
undergoes β-elimination to form IFM. The enzymes required for the first bioactivation
are CYP 3A4, 3A5 and 2B6 [28-30]. Tumor cells in general, have inherently lower
levels of cytochrome P450 enzymes [82-85]. Specifically, studies demonstrate that
neuroblastoma cells are unable to activate IFO, resulting in no cytotoxicity[84], while
there was considerable cytotoxicity when either rat liver microsomes or pre-activated 4hydroxyIFO were used. Consequently, in vitro, IFO should result in little to no toxicity
in both rhabdomyosarcoma and neuroblastoma cell lines. As expected our results
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corroborated these findings, with IFO showing no death in either cell line until
extremely high concentrations of 5 mM. While cell death was observed at high
concentrations, normal plasma concentrations of IFO are between 50 and 800 uM [86],
suggesting us that such high concentrations are not clinically relevant.
In vitro then, the use of liver microsomes to bioactivate IFO or a pre-activated
form such as IFM itself is required; we chose the latter. As expected, our results showed
a dose dependant decline in tumor cell viability with increasing concentrations of IFM.
It is important to note that in humans, the majority of IFO metabolism occurs
hepatically, following which IFM is transported in erythrocytes to the tumor tissues,
where passive diffusion or transporter mediated process allow entry into tumor cells
[87]. Therefore the lack of bioactivating enzymes in cancer cells will not prevent their
exposure to IFM in vivo.
The dose of IFM used when assessing the potential effects of NAC was one that
produced greater than 50% cell death. However cell kill was not 100%. This is
important for being able to assess both the potential positive and negative effects NAC
might have. In terms of clinical relevance, this dose is also within the reported range of
plasma concentrations of IFM [87-89]. As discussed previously, NAC, both in the form
a concurrent and pretreatments, had no impact on the cancer cell cytotoxicity of IFM.
Futhermore NAC + MESNA treatments also had no impact of IFM activity. This is
important, as MESNA is a standard adjuvant to IFO therapy for the protection of
bladder toxicity [15, 45]. Therefore these results suggest that potential combination of
both chemoprotectants NAC and MESNA will not affect IFM efficacy. The fact that
neither NAC nor MESNA interact with the efficacy of IFM can be explained by a lack
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of complete understanding as to the mechanism of cell death caused by IFM. It has
widely been assumed that since apoptosis is the main form of cell death causes by IFO,
ROS must play a pivotal role, and therefore suggesting that addition of any antioxidant
might interrupt the apoptotic pathway. However, to our knowledge, no study has looked
at the presence of ROS during IFO-mediated cell death and in fact, little is known
regarding how cell death occurs following DNA alkylation. Further to this point,
Sentruker et al. [90] demonstrate that upon evaluation of two chemotherapy drugs
commonly associated with oxidative damage as their mechanism of cancer cell death,
neither in fact produced any increases in ROS. Therefore, both etoposide and cisplatin
antitumor effects may not involve oxidative stress as once accepted. Similarly, the lack
of inhibitory effects of NAC, as well as other antioxidants such as MESNA,
thymoquinone and melatonin on IFO cancer cell kill, might suggest the same is true for
IFO.
This study is the first to demonstrate that NAC does not interfere with the
antitumour efficacy of IFM and is an important first step in demonstrating the clinical
utility of NAC. The next reasonable step includes assessing the effects of NAC in
tumor xenograft animal model, which will further our understanding of any effects
NAC might have on IFO efficacy. This is a critical step, which will provide important
information regarding the NAC’s ability to improve the risk/benefit ratio of IFO use and
may further support its use in preventing nephrotoxicity in children, in a clinical setting.
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4.1 Introduction
Currently, the 5-year survival rate for children diagnosed with cancer is 82%,
compared to 50% thirty years ago [1, 2]. It is now estimated that 1 in 1000 adults living
in the United States are survivors of childhood cancer [2]. The increasing numbers of
childhood cancer survivors has highlighted the previously underappreciated problem of
potential long-term adverse effects of chemotherapy. As survival rates in this population
increase, so does the overall number of people suffering from late effects and/or
suboptimal health conditions, secondary to initial presentation of cancer and therapy [3].
Two thirds of the adults who have survived their childhood cancer suffer from an
adverse condition as a result of their cancer treatment. Late effects occurring in one
third of these adults may be severe or life threatening [4, 5].
Nephrotoxicity is an adverse effect that can be caused by the antineoplastic drug
ifosfamide (IFO). This is an age dependent problem, with up to 30% of children who
receive IFO therapy suffering varying degrees of nephrotoxicity. In the most severe
cases, IFO treatment may result in Fanconi syndrome, a proximal tubule dysfunction
that can produce hypophosphatemic rickets, necessitating lifelong supplementation with
phosphate and bicarbonate [6, 7]. It may also result in severe glomerular toxicity
leading to acute or chronic renal failure, requiring renal dialysis and/or renal
transplantation [8, 9]. IFO is used in children primarily for the treatment of Ewing’s
sarcoma, rhabdomyosarcoma, osteosarcoma, neuroblastoma, as well as acute
lymphoblastic leukemia and non-Hodgkin’s lymphoma [10-14]. While severe
urotoxicity was previously the dose-limiting toxicity associated with IFO, concomitant
administration of sodium 2- mercapto-ethanosulphonate now provides uro-protection.
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Consequently, nephrotoxicity has emerged as the most severe toxicity associated with
IFO use [14, 15].
IFO is a pro-drug that undergoes metabolic activation to produce the active
cytotoxic agent ifosfamide-mustard: the relatively low cytotoxicity of the parent drug
reduces undesirable toxicity in most non-tumour tissues. However, the toxic metabolite
chloroacetaldehyde (CAA), produced during IFO metabolism, appears to be responsible
for toxicity against the kidney [16-19]. Produced locally in the kidney [20], CAA is
generated via side-chain oxidation of IFO. The alternative pathway to ring
hydroxylation, that produces the active antineoplastic agent IFO mustard, and acrolein
(Figure 1.2). Acrolein is the metabolite responsible for bladder toxicity [16, 21, 22].
Both side chain oxidation and ring hydroxylation metabolism of IFO (via the
cytochrome P450 isozymes 3A4, 3A5 and 2B6) occur in equimolar amounts in both the
liver and in the renal tubule cells. Thus, the kidney is capable of producing toxic
metabolites intra-renally [20, 23-25].
CAA toxicity occurs through oxidative stress, suggesting the potential for the
use of an antioxidant to mitigate IFO-induced renal toxicity. While several antioxidants
have been investigated as potential therapeutics for renal toxicity associated with IFO,
n- acetylcysteine (NAC) is the most suitable agent. Although other antioxidants such as
thymoquinone [26)[, resveratrol [27], taurine [28], l-histidinol [29], and melatonin [30]
act much like NAC and provide protection through their activity as nucleophiles, by
scavenging toxic reactive oxygen species, NAC is clinically distinct from the others.
NAC acts as a precursor to glutathione, depletion of which is a key characteristic of
IFO-induced nephrotoxicity. Importantly, NAC is also commonly used clinically [31,
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32] as the drug of choice in children and adults for treatment of acetaminophen
overdose using a 21-hour IV protocol (5, 33). This provides valuable information
supporting future use of NAC in combination with IFO, since the previous use of NAC
in children provides a reassuring record of safety in this vulnerable population in which
safety data is often difficult to obtain. Furthermore, our group has generated evidence
supporting the therapeutic efficacy of NAC as a promising mitigator of renal toxicity
secondary to IFO. Both in vitro [34] and in vivo [35] studies in rats have demonstrated
that clinically relevant concentrations of NAC are able to mitigate IFO-induced renal
toxicity in models of Fanconi syndrome. We have further demonstrated that NAC doses
described above for acetaminophen overdose are likely to be sufficient for renal
protection [36].
When considering the contribution of IFO to late effects it is important to
recognize the extent of its use. Based on Canadian pediatric cancer statistics between
2000 and 2004, we have estimated that IFO may have been part of chemotherapy
protocols used to treat as high as 25% of children with cancer [1]. This highlights the
need for approaches that protect the long-term health of childhood cancer survivors, and
emphasizes the extent to which IFO may contribute to such late effects. However, any
concurrent therapy must be demonstrated not to interfere with eradication of neoplastic
cells and cancer cure rates. While NAC shows promise in the protection against late
effects caused by IFO, it should first be shown that it does not interfere with the ability
of IFO to be an effective chemotherapeutic agent before it can be used clinically. In this
study we assessed the potential of NAC to affect the efficacy of IFO.
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4.2 Materials and Methods
All experimental protocols described here were approved by the University of
Western Ontario Animal Care and Use Council.
4.2.1 Mice
Female NIH-III (nude homozygous) mice (28-42 days) were purchased from
Charles River Canada (Montreal, QC, Canada). Mice were kept at a constant
temperature and regular light cycles of 12-h light and dark, under pathogen-free
conditions. They were fed Harlan-Teklad diet 2919 and water ad libitum.
4.2.2 Tumor cells
Experiments were carried out using a Ewing’s sarcoma xenograft model, as
described by Sanceau et al. [37]. EW- 7 cells (wild-type p53 primary tumours localized
to the scapula) [37] were a kind gift from Dr. O. Delattre (Institute Curie, Paris, France).
PCR-based testing for pathogen, confirmed that cells were free of mycoplasma or
common rodent viruses (IMPACT II test, IDEXX RADIL, Columbia, Missouri, USA).
Cells were cultured in standard RPMI tissue culture medium supplemented with 10%
fetal bovine serum and L-glutamine (2 mM) and grown in collagen coated tissue culture
flasks. They were initially established as transplantable tumours (maximum volume of
1000 mm3) by subcutaneous injection of 20 x 106 cells into the flanks of female NIH-III
mice. Thereafter, xenografts were maintained in vivo by sequential passaging of
subcutaneous implants of tumour fragments, as described below in Experimental
Design, with an engraftment success rate exceeding 90%.
4.2.3 Reagents
NAC was purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada).
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Ifosfamide was purchased from Baxter Oncology GmbH and Baxter Corporation
(Mississauga, ON, Canada). Collagen I, bovine was manufactured by Gibco and
purchased from Invitrogen Corporation (Burlington, ON, Canada). RPMI1640 was
purchased from Wisent Bioproducts (St. Bruno, QC, Canada).
4.2.4 Experimental Design
EW-7 tumour xenograft fragments (approximately 10-20 mm3) were surgically
implanted into the flank of mice according to a protocol described by Morton and
Houghton (ref. 38; procedures 1, 2b, 3, 4, 5a and 6 described therein) under Avertin
(tribomethanol)-induced anaesthesia. When tumours reached a volume of 50-100 mm3,
the mice were randomly assigned into one of the following groups (n=5 per group).
(1) Saline-treated control group: 0.9% saline (in 0.3 ml, intraperitoneally (IP))
daily for 6 days.
(2) NAC group: NAC (1.2 g/kg in 0.3 ml 0.9% saline, pH 7.2 IP) daily for 6
days. This dose was identical to that capable of preventing IFO-induced
nephrotoxicity in rats [35]. NAC doses as high as 1.2 g/kg have been reported
not to induce any deleterious effects [39].
(3) IFO group: IFO (60 mg/kg in 0.3 ml 0.9% saline, pH 7.2 IP) daily for 3 days.
(4) Concurrent NAC + IFO group: IFO plus NAC (60 mg/kg IFO and 1.2 g/kg
NAC, both in 0.3 ml 0.9% saline, pH 7.2 IP) daily for 3 days, followed by 3
additional days of NAC treatment alone.
(5) Pretreatment NAC + IFO group: NAC (1.2 g/kg in 0.3 ml 0.9% saline, pH
7.2 IP) daily for 6 days, followed by IFO (60 mg/kg in 0.3 ml 0.9% saline, pH
7.2 IP) daily for 3 days.
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Tumours were allowed to grow until the fastest-growing tumor of each mouse
reached a volume of 1000 mm3, at which point the mouse was euthanized.
4.2.5 Outcome measures
Tumour volumes were estimated every 2 days by caliper measurements
(volume=0.52 (length x width2)) until euthanasia.
4.2.6 Statistical analysis
Control and treatment groups were compared using the Mann-Whitney U-test,
as indicated. Values are presented as medians±interquartile range.

4.3 Results
4.3.1 Effect of ifosfamide on EW-7 Ewing xenograft growth
We investigated the effects of NAC on IFO efficacy in a tumor xenograft mouse
model. When EW-7 tumours in host mice reached the target size (approximately 100
mm3) they were subsequently treated with IFO. Tumour growth was significantly
inhibited in the IFO treatment group (n=8) compared to growth of tumours in control
mice treated with saline alone (n=6) (Figure 4.1).
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Figure 4.1 The effect of ifosfamide on EW-7 xenograft growth. Starting at day 1, mice
received IFO (60 mg/kg IP) daily for 3 days or 0.9% saline alone, daily for 6 days
(control). Values plotted are median ± interquartile range; medians were significantly
different when compared by the Mann Whitney U-test (+p<0.05; ++p<0.01).
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4.3.2 Effect of concurrent n-acetylcysteine + ifosfamide on EW-7 xenograft growth
Mice with established EW-7 tumours were treated concurrently with both NAC
and IFO, and with follow-on treatment with NAC alone, in order to determine whether
the growth-inhibiting capacity of IFO was affected by NAC. When treated with both
IFO and NAC daily for 3 days, followed by 3 days of NAC alone (n=7), EW-7
xenograft tumour volumes were significantly smaller than in control, saline-treated mice
(n=6) (Figure 4.2). When tumours in mice treated with IFO alone (n=8) were compared
with those in mice treated concurrently with both NAC and IFO (n=7), it was clear that
NAC had no effect on the capacity of IFO to inhibit tumour growth: IFO inhibited
tumour growth with equal efficiency in both NAC-treated mice and in mice without
NAC treatment (Figure 4.2). In fact, tumours in mice treated concurrently with both
NAC and IFO had median volumes that were numerically lower (although not
significantly different) than in mice treated with IFO alone.
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Figure 4.2 The effect of concurrent NAC + IFO on EW-7 xenograft growth and IFO
efficacy. Starting at day 1, mice received IFO (60 mg/kg IP) + NAC (1.2 g/kg IP) daily
for 3 days, followed by 3 days of daily treatment with NAC alone, IFO alone (60 mg/kg
IP) daily for 3 days or 0.9% saline alone daily for 6 days (control). Plotted values are
median ± interquartile range; medians were significantly different when compared by
the Mann Whitney U-test) (+p<0.05 and ++p<0.01 when IFO is compared to control;
*p<0.05 when NAC + IFO is compared to control).
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4.3.3 Effect of pre-treatment n-acetylcysteine + ifosfamide on EW-7 xenograft growth
Mice were also pre-treated with NAC, followed by IFO, in order to determine
whether pre-existing NAC in whole animals and/or xenografted tumour environment
affected the capacity of IFO to inhibit EW-7 xenograft growth. Pretreatment with NAC
daily for 6 days followed by IFO daily for 3 days (n=6), resulted in inhibition of EW-7
xenograft tumour growth and, furthermore, comparison of tumors in mice treated with
IFO alone with those in mice pre-treated with NAC before IFO treatment revealed that
NAC pretreatment had no effect on the capacity of IFO to inhibit EW-7 tumor growth
(Figure 4.3). As with concurrent NAC and IFO therapy, tumors in mice pre-treated with
NAC before IFO administration had median volumes that were numerically lower
(although not significantly different) than in mice treated with IFO alone.
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Figure 4.3 The effect of pre-treatment with NAC followed by IFO treatment on EW-7
xenograft growth and IFO efficacy. Starting at day 1, mice were treated with NAC
alone (1.2 g/kg IP) daily for 6 days, followed by IFO (60 mg/kg IP) daily for 3 days,
IFO alone (60 mg/kg IP) daily for 3 days or 0.9% saline alone daily for 6 days (control).
Plotted values are median ± interquartile range; medians were significantly different
when compared by the Mann Whitney U-test (+p<0.05 and ++p<0.01 when IFO is
compared to control; *p<0.05 and **<p<0.01 when pre-treatment with NAC + IFO is
compared to control).
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4.3.4 Effect of n-acetylcysteine alone on EW-7 xenograft growth
The effect of NAC alone on EW-7 xenograft growth was assessed in comparison
with saline-treated controls. While NAC alone resulted in lower median tumor volumes
on days 65 and 68 following treatment, tumor volumes at all other time points were not
significantly different between NAC- and saline- treated mice, suggesting that the
effects of NAC alone on tumor growth in this test system are either negligible or nonexistent (Figure 4.4).
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Figure 4.4 The effect of NAC on tumor volumes. Starting at day 1, mice were treated
with NAC (1.2 g/kg IP) daily for 6 days, or daily with 0.9% saline for 6 days (control).
Values plotted are median ± interquartile range; medians were significantly different
when compared by the Mann Whitney U-test (*p<0.05).
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4.4 Discussion
NAC possesses characteristics that make it a promising chemoprotectant against
IFO-induced renal injury. As it is currently approved against acetaminophen overdose
in children [5, 33], safety data are available to allow its safe use for this potential new
indication. Children with cancer are a vulnerable population and therefore sufficient
evidence for the safety of NAC for this population is imperative before its clinical use
as a renal protectant. Critically, there is a large body of evidence supporting the
effectiveness of NAC in renal protection during IFO therapy. Our group has
demonstrated the therapeutic efficacy of NAC in protecting against IFO-induced
cytotoxicity and glutathione depletion in a proximal tubule cell line, as well as IFOinduced nephrotoxicity in a rodent model of Fanconi syndrome [34, 35]. In vivo, NAC
prevented renal tubular morphological damage, reduced glutathione (GSH) levels,
glutathione S-transferase activity and lipid peroxidation, as well as prevented elevated
levels of serum creatinine, magnesium and β2-microglobulin in rats treated with IFO
[35]. Furthermore, regarding the clinical utility of NAC, we demonstrated that the
current dose of NAC used in acetaminophen poisoning (the 21-hour IV dose protocol)
should provide a sufficient dose for renal protection based on our translational
pharmacokinetic work [36]. Our recent pharmacokinetic study compared the systemic
exposure of NAC between our therapeutically effective rodent model and children
receiving NAC for acetaminophen overdose, showing similar systemic exposures
between both groups. We also analyzed 2 cases of children with cancer experiencing
IFO-induced renal injury, following which, NAC was added concurrently to their
treatment plan. In both cases, following NAC treatment, the renal impairment was
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reversed, further supporting the experimental findings [36]. However, while all the
studies to date support the effectiveness of NAC, it must first be confirmed that it does
not interfere with the antitumor activity of IFO before it can be evaluated in the context
of a clinical trial. In vitro studies using rhabdomyosarcoma and neuroblastoma cell lines
have demonstrated that NAC does not interfere with the cytotoxicity of the active
metabolite IFO mustard [40]. To further support this, the results of this in vivo study
demonstrated that both pre-treatment and concurrent therapy with NAC show no
evidence of interference with IFO efficacy. As discussed in greater detail below, both
treatments not only significantly reduced human EW-7 tumor xenograft growth
compared to saline treated mice, but more importantly, there was no significant effect of
NAC (at doses expected to reduce renal toxicity) on the potential of IFO to treat EW-7
tumors.
While our study did not assess the effects of either IFO and/or NAC on the renal
function of the mice, both doses of NAC and IFO have been investigated in this context
in animal models. Of greatest importance, the dose of NAC in this study (1.2 g/kg daily
for 6 days) is the dose that our group previously demonstrated to provide protection to
the kidneys of rats treated with IFO [35]. As discussed above, this dose of NAC
prevented urinary loss of solutes such as magnesium and β2-microglobulin, and serum
increases in creatinine, and protected against GSH depletion, lipid peroxidation,
decreased glutathione S-transferase activity, and morphological damage to renal tubules
[35]. Furthermore, doses of IFO as low as 40 mg/kg daily for 3 days have been shown
to produce Fanconi syndrome resulting in phosphaturia, glucosuria, aminoaciduria,
changes in membrane phospholipid composition, and glutathione depletion [41]. Our
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group used an IFO dose of 60 mg/kg daily for 3 days. These data suggest that both the
dose of IFO and NAC are sufficient to induce Fanconi syndrome and protect against it,
respectively.
We chose the EW-7 Ewing xenograft model based on the successful use of
those cells by Sanceau et al. [37], and the high relevance of Ewing’s sarcoma as the
second most common bone cancer among children [42, 43]. In order to provide a useful
experimental model, the concentration of IFO selected for treatment of xenografts must
be effective in moderately reducing tumor volumes, but should not result in complete
ablation of tumors. The capacity of NAC to either inhibit or enhance IFO efficacy,
would therefore be ascertainable. The concentration of IFO selected for this study (60
mg/kg daily for 3 days) fulfilled this requirement (Figure 4.1). IFO treatment alone for 3
days reduced median EW-7 tumor volume compared to saline treatment but did not
induce complete tumor disappearance. Thus, our model was suitable to assess either the
positive or negative effects of NAC on IFO activity.
Concurrent NAC and IFO treatment of mice bearing EW-7 tumors led to
significantly lower median tumor volumes compared to control mice (Figure 4.2). This
demonstrated that NAC plus IFO therapy is effective in reducing EW-7 tumor volumes.
However, while important, these data did not evaluate the potential effect of concurrent
NAC treatment on IFO efficacy. The comparison between NAC plus IFO, and IFO
alone, on EW-7 tumor growth allowed this evaluation. We showed that IFO reduced
tumor growth, and that its potential was unaffected by concurrent NAC treatment
(Figure 4.2). NAC had therefore no negative effect on the ability of IFO to reduce tumor
volumes.
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The effect of pre-treatment with NAC was also assessed. Evaluation of both
concurrent and pre-treatment strategies allows for flexibility when determining
treatment regimens in a clinical setting. Similar results were seen in mice pre-treated
with NAC, followed by IFO therapy. A comparison of pretreatment with NAC plus IFO
to control saline-treated mice shows that this therapy is capable of reducing EW-7
tumor volumes (Figure 4.3). Furthermore, a comparison between pretreatment NAC
plus IFO with IFO alone showed no significant difference between the two with respect
to median tumor volumes (Figure 4.3). Therefore, NAC administered concurrently with
IFO, or prior to IFO treatment, had no effect on IFO efficacy; there was a similar IFOinduced reduction in EW-7 tumor volumes regardless of addition of NAC to the
treatment. This further reinforces the fact that it is unlikely that NAC will interfere with
the clinical efficacy of IFO. These results are in accordance with other studies reporting
a lack of effect of NAC on the capacity of other chemotherapeutic agents to inhibit
tumor growth. Carboplatin, etoposide, and doxorubicin, along with several other agents,
have all been shown to maintain their chemotherapeutic efficacy in the presence of
NAC [44, 45]. This further strengthens the implication of this study that NAC is
unlikely to negatively affect the efficacy of these agents.
As outlined above, there is a large body of evidence supporting the use of NAC
as a prophylactic treatment for IFO-induced nephrotoxicity. While the data presented in
this article are important in realizing the use of NAC clinically, the fact that IFO is not
generally used as a single-agent raises the concern that NAC may interfere with the
efficacy of other chemotherapy agents used in combination with IFO. It therefore
becomes important to review protocols in which IFO combinations exist. IFO is
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identified for use in combination with etoposide, doxorubicin, cisplatin, cytarabine,
cyclophosphamide, and carboplatin [46-50, 51,52]. Data assessing the potential effects
of NAC on the efficacy of these drugs are already available. Etoposide, doxorubicin or
carboplatin, when administered concurrently with NAC, induce no changes in cytotoxic
activity [45, 53]. While cyclophosphamide has yet to be evaluated with NAC, it is an
analogue of IFO, differing only in one chloroethyl group and sharing the same
qualitative metabolic profile. It is therefore reasonable to predict that it will act in the
same manner as IFO and, when administered in combination with NAC, it will not have
reduced efficacy. Finally, while there is evidence to suggest that NAC interferes with
cisplatin by conjugating and rendering it incapable of entering the cell, it has also been
demonstrated that altering the time and site of administration of NAC and cisplatin
allows for effectiveness of both treatments [44, 54].

4.5 Conclusion
We present data suggesting that concurrent or pre-treatment with NAC at
concentrations capable of preventing IFO-induced renal toxicity does not affect IFO
antitumor activity in vivo. While IFO is commonly used in combination therapies,
numerous available studies suggest that these combinations will not be negatively
impacted by NAC therapy, similar to the lack of inhibitory effects of NAC on IFO
efficacy, demonstrated in the present study. We conclude that there is a strong basis on
which we can proceed in testing the use of NAC to prevent IFO-induced nephrotoxicity
in children, even among combination therapies. This study further strengthens the need
for a randomized clinical trial of NAC as a renal protectant for children with cancer.
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Chapter 5: Overall discussion and future directions
Part of this chapter has been published:
Hanly L, Rieder MJ, Huang SS, Vasylyeva TL, Shah RK, Regueira O, and Koren G.
N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.
Journal of Population Therapeutics and Clinical Pharmacology. Journal of Population
Therapeutics and Clinical Pharmacology. 2013;20(2):e132-45.
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5.1 Preamble: Future directions and overall perspective
In this alternate thesis structure, each chapter has been already published in the
peer review literature with its own discussion section. Considering the evidence
described in this thesis, along with the immediate need to address the issue of how
clinicians and hospitals should prevent and treat nephrotoxicity caused by IFO, I have
selected to focus this overall discussion section on the synthesis of clinical protocol
recommendations for NAC rescue therapy to prevent IFO nephrotoxicity in children.
While we do believe there is sufficient evidence to treat those patients who present with
kidney toxicity, this protocol does not obviate the need for a randomized control trial
(RCT). We have designed a prospective RCT to determine the effectiveness of NAC a
prophylactic strategy against IFO-induced nephrotoxicity. This chapter concludes with a
discussion and overall perspective.

5.2. N-acetylcysteine rescue protocol for nephrotoxicity in children caused by
ifosfamide
5.2.1 Introduction
In the United States alone, there are over 270, 000 adult survivors of childhood
cancer [1], among whom a majority are suffering from late effects secondary to their
cancer treatment. These survivors have health problems that may seriously affect their
quality of life, and/or may be life threatening [2]. Nephrotoxicity, primarily manifesting
as proximal tubule dysfunction, in particular can be a devastating late effect which may
necessitate lifelong supplementations, renal dialysis and renal transplant, and in severe
cases may result in death [3]. The chemotherapy agent ifosfamide (IFO) is among the
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most common causes of chemotherapy-related renal damage [4] and despite a large
body of preclinical evidence supporting the effectiveness of n-acetylcysteine (NAC) as
a concurrent therapy for IFO-related permanent kidney damage, its use has yet to be
adopted regularly in a clinical setting. We summarize below two published case reports
wherein NAC was successfully used as renal protectant during IFO treatment, and
report for the first time, a third successful case. The objective of this document is to
summarize the evidence supporting the use of NAC as a treatment for children suffering
from IFO nephrotoxicity and to present a NAC rescue protocol. It is hoped that
additional clinicians will join those who have followed this protocol in order to develop
a prospective randomized trial.
5.2.1.1 Ifosfamide
IFO is an antineoplastic agent used in the treatment of pediatric solid tumours,
including Ewing’s tumours, ostesarcoma, rhabdomyosarcoma, and non-hodgekins
lymphoma, as well as acute lymphoblastic leukemia [5, 6]. While a proven treatment in
the battle against childhood cancer, with regimens including IFO having a higher cure
rate for most cancers than its analogue cyclophosphamide [7], IFO use does not come
without consequences. Nephrotoxicity affects up to 30% of children who are treated
with this agent [3, 8]. While these children may benefit from its antineoplastic potential
and be cured of their cancer, their health and quality of life may be seriously impacted
by this late effect.
IFO, a nitrogen mustard, is a prodrug, which is metabolized to the active
antineoplastic agent IFO-mustard [9]. Metabolic activation to IFO mustard occurs via
ring hydroxylation by CYP P450 3A4, 3A5, and 2B6 yielding both IFO mustard and
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acrolein [9] (Figure 1.2). IFO may also be metabolized via the alternate metabolic
pathway, side chain oxidation, producing 2- and 3-dechloroethyl IFO and
chloroacetaldehyde (CAA)[9, 10]. Both acrolein and CAA are toxic reactive
metabolites that are known to be responsible for some of the toxicities associated with
IFO use [10, 11].
Neurotoxicity, myelosuppression, GI toxicity, nephrotoxicity and urotoxicity
have all been identified as adverse effects of IFO chemotherapy, with the latter two
being the most severe [4]. In the past, IFO use was limited by the commonly occurring
and severe urotoxicity. However this late effects has been overcome with the coadministration of 2-mercaptoethanosulphonate (MESNA), a synthetic thiol which
protects the bladder epithelium against the reactive metabolite acrolein, allowing for an
almost complete reduction in the incidence of urotoxicity. This allowed for the ability to
increase both dose and frequency with which IFO was given, following which
nephrotoxicity emerged as the most severe, and dose limiting toxicity [4].
5.2.1.2 Nephrotoxicity
Cumulative dose, unilateral nephrectomy, prior platinum therapy and age, are all
risk factors predisposing patients to kidney toxicity [3]. With respect to those affected,
nephrotoxicity presents in each child to varying degrees. 30% of children who are
treated with IFO will suffer mild to moderate renal dysfunction with 5% suffering from
its most severe form Fanconi syndrome [3, 8]. Presenting as a proximal tubule
dysfunction, Fanconi syndrome results in urinary loss of important solutes such as
glucose, amino acids, B2 micoglobulin, phosphate and bicarbonate[8]. It may lead to
renal tubular acidosis and/or hypophosphatemic rickets, and the need for lifelong
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supplementation with phosphate, bicarbonate and potassium [12, 13]. Up to 30% of
children may also suffer from declining glomerular function, resulting in the need for
dialysis, renal transplant, and/or causing death [8]. Treatment options are limited to
supportive care with most children seeing little to no improvement in their renal
function overtime and many seeing persistent declines in renal function [8] (Table 1.1).
The metabolite CAA, formed by side chain oxidation of IFO, is responsible for
this late effect associated with IFO [14]. However, studies show that systemic
concentrations of CAA do not correlate with severity of nephrotoxicity, suggesting
hepatic metabolism of IFO does not play a role in kidney toxicity [15]. Of importance,
while the majority of xenobiotic metabolism is thought to be hepatic, there is evidence
that the kidney is also capable of such biotransformation [11]. Moreover, there are
studies available that demonstrate that in the case of IFO, the kidney possesses the
enzymes responsible for its metabolism and is capable to producing levels of CAA
which in turn have been shown to be toxic to kidney tubules [11, 14, 16]. Therefore the
kidney “creates its own poison”, and when unable to detoxify at the same rate with
which it is being produced, this results in toxicity.
The mechanism by which CAA exerts its toxicity within the kidney is due
increased oxidative stress. Increases in reactive oxygen species and products of lipid
peroxidation [17], as well as increased calcium and sodium concentrations have been
demonstrated effects of CAA[18, 19]. While increased calcium can be detrimental to
the cell, causing damage to the cytoskeleton, cell membrane, and potentially causing
cell death, low levels of sodium are important for proper solute reabsorption, this being
a hallmark of Fanconi syndrome [20, 21]. CAA may also result in loss of mitochondrial

159
membrane potential, depletion of ATP and increases in pro-inflammatory cytokines
TNF-α, IL-1β and IL 6[22-24]. Given the primary mechanism of CAA toxicity is
oxidative damage, most crucial, is the depletion of glutathione (GSH) as a result of
CAA [14, 17, 25]. As our intracellular protective mechanism against oxidative stress,
GSH’s ability to protect against CAA become critical to cell survival in environments
with increased oxidative stress.
5.2.1.3 N-acetylcysteine
Much like in the way that MESNA, routinely given with IFO, protects the
bladder, there is hope for such an antidote for kidney toxicity. With an awareness of the
mechanism through which CAA exerts its toxicity it becomes easier to define this
promising prophylactic and/or rescue strategies. With strong evidence supporting the
main mechanism of kidney toxicity as oxidative stress, with a critical depletion in GSH
[17, 25, 26], antioxidants are a promising strategy. While several antioxidants such as
resveratrol, thymoquinone, melatonin, taurine, glycine and L-histidinol have been
assessed in the prevention of IFO-induced nephrotoxicity[19, 24, 26-30], none of these
options directly addresses the issue of glutathione depletion. More importantly, none of
these compounds are currently used clinically in children for any indication. Our group
has chosen to assess the protective potential of NAC against IFO nephrotoxicity. Not
only does NAC function as a nucleophile, detoxifying ROS, it also acts as a precursor to
glutathione synthesis by providing the cysteine essential for its formation [31, 32]. Even
further to the advantage of NAC, is that it is currently used clinically in children for
acetaminophen overdose[31, 32, 33 ]. This provides safety data that is not only
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unavailable for alternative protective strategies, but can be very difficult to obtain in
vulnerable populations such as children.
Currently used in the 21-hour IV schedule for acetaminophen overdose
worldwide, this dose, along with several oral protocols (72 and 36 hours) have been
demonstrated to exhibit similar efficacy when given within the 8 hour window
following poisoning [34], with the 36 and 72 hour oral and 48 hour IV protocols being
more effective for late treated patients [35, 36]. These protocols also demonstrate
similar safety (Table 2.3). With respect to adverse events, they include anaphylactoid
reactions when receiving IV formulations however more common side effects include
nausea and vomiting when taken orally [37]. Anaphylactoid reactions are generally
attributed to infusion rate. While they have been reported to occur in as little as 0% of
patients to as many as 48%, they are generally minor and easily managed. [38]. In most
cases NAC infusion can be continued and completed following treatment of the reaction
and administration of diphenhydramine [39-41]. Also important, is the established
safety of repeated or chronic NAC use. Oral NAC is often used in the treatment of
chronic obstructive pulmonary disease (COPD) and is used safely for extended periods
of time ranging from 22 weeks to 6 months. Chronic use of NAC in these patients
resulted in minimal side effects, of which the most common were gastrointestinal; in all
cases NAC therapy remained uninterrupted [42]. These characteristics make NAC not
only a promising choice for kidney protection during IFO therapy but also the most
readily available for immediate use.
5.2.2 Supporting Evidence
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Prophylaxis is defined as prevention of disease, while treatment is defined as
remedy of disease. We present below evidence for NAC use, both as prophylaxis and
treatment, for IFO-induced nephrotoxicity. We reiterate here, that we choose to discuss
NAC rather than other treatment options, which have also successfully protected against
IFO-induced nephrotoxicity in animal models, because we believe that NAC is
currently the most clinically relevant choice. This is not to suggest that the other agents
may not be equally effective or even more potent than NAC, as a direct comparison of
the chemicals has never been done. We do however argue that the lack of information
of the safe use of these chemicals in children severely hinders their ability to be used in
a clinical setting in the near future, until appropriate safety data is collected. The
availability of this information for NAC, allows it to be used in a more immediate
manner, allowing for prevention/treatment of IFO-nephrotoxicity sooner than with the
other treatments. Should one of these other treatments be deemed superior to NAC and
have adequate safety date, a re-evaluation of the best treatment for IFO-nephrotoxicity
should be done.
5.2.2.1 Evidence supporting n-acetylcysteine for prophylaxis
There is large body of evidence to date to support the clinical use of NAC to
prevent IFO renal toxicity. NAC has been efficacious in protecting against IFO-induced
renal toxicity in both cell and rodent models [17, 25]. LLCPK-1, porcine renal proximal
tubule cells, treated with IFO have depleted levels of glutathione and significant cell
death. Treatment with NAC partially protects against glutathione depletion, and fully
protects against decreased cell viability[25]. NAC also displays similar protective
effects in a rodent model of nephrotoxicity. In these animals, IFO resulted in depletion
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of glutathione, reduced glutathione-s-transferase activity and increases in products of
lipid peroxidation. IFO also resulted in morphological damage to tubules and glomeruli,
increased levels of serum creatinine and increased urinary excretion of β2microglobulin and magnesium. With co-administration of NAC, rats were protected
against all parameters of early stages of Fanconi syndrome. Lipid peroxidation as
measured by malondialdehyde and 4-hydroxyalkenal increases, and decreases
glutathione S-transferase activity were both restored to control levels. However in
contrast to the in vitro model, full rather than partial protection against GSH depletion
was seen [17]. Morphological damage including distorted tubules and degenerated
glomeruli, as well as interstitial inflammation and oedema, seen with IFO treatment,
was not present in NAC treated group. Our group has also done translational work
demonstrating that the 21-hour IV dose of NAC used in children for acetaminophen
poisoning, provides comparable systemic exposure when compared to our
therapeutically effective rodent model, which as discussed above is protected at early
stages of IFO- induced Fanconi syndrome. This suggests that the 21 hour IV dose of
NAC should also be sufficient in providing renal protection [43] supporting the choice
of 21 hour IV protocol over other oral protocols.
While studies of efficacy are critical to the use of NAC clinically, just as
important is work assessing the effects of NAC on the antineoplastic ability of IFO.
Both in vitro and in vivo work exists which shows no evidence that NAC interferes the
chemotherapeutics effects of IFO. In two relevant cancer cell lines, rhabdomyosarcoma
and neuroblastoma, IFM treated cancer cells retained their ability to kill with both the
addition of NAC and NAC + MESNA combination [44]. The addition of MESNA,
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routinely administered with IFO for uroprotiection, was included to ensure that a
combination of these chemoprotectant, would also not interfere with IFM efficacy.
Furthermore, in a mouse xenograft model, where mice were implanted with Ewing’s
sarcoma tumours, treatment with NAC and IFO, retained the same ability to inhibit
tumour growth as IFO alone treated mice, when both were compared to control. While
not significant, NAC + IFO treated mice has small tumor volumes, than mice treated
with IFO alone. These studies suggest that ability of IFO to retain its alkylating
properties against tumour cells, even in the presence of NAC [45]. Further supporting
these findings is work which suggests that the addition of NAC to IFO treatment does
not affect IFO pharmacokinetic parameters such as plasma half life, area under the
curve, and plasma clearance [46].
5.2.2.2 Evidence supporting n-acetylcysteine for treatment
While the previous evidence suggests a prophylactic strategy, case reports,
collected from circumstances in which treating physicians deemed NAC intervention a
necessity following presentation of nephrotoxicity, also provide evidence that NAC can
be used not only for prevention but treatment as well.
The most convincing support for the clinical use of NAC in children suffering
from renal dysfunction are two case reports which have already been described in the
literature, in addition to the third described below, of children who received NAC
during, or just following, IFO containing chemotherapy regimens after demonstrating
signs of renal dysfunction. The first case report describes a 10-year old girl who
presented with primitive neuroectodermal tumour of the Ewing’s sarcoma family and
acute renal failure. Following unsuccessful surgery, she was treated with IFO (3g/m2),
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vincristine (1.5mg/m2), dactinomycin (1.5mg/m2), and MESNA on day 1, and IFO
(3g/m2) and MESNA only on day 2 and 3, followed by dialysis on each day. She was
also given the 21 hour IV dose of NAC on day 1 and 2. AUC’s of NAC calculated for
these two days were similar to AUC’s observed in children treated with this dose of
NAC for acetaminophen overdose. Following treatment this child had no clinical or
laboratory signs of renal damage and she showed all signs of tumour lysis. The second
case report describes a 15-year old male who had recurrence of mixed germ cell
testicular cancer. He had elevated levels of serum creatinine (1.2-1.6mg/dl), which
remained high following his chemotherapy regimen of cisplatin, etoposide and
bleomycin. Following an abdominal relapse, he was treated with a protocol including
Paclitaxel 257 mg, carboplatin 653 mg, IFO 3400 mg, and MESNA 684 mg on day 1,
and IFO 3400mg and MESNA only on days 2-5. The patient’s serum creatinine steadily
rose following treatment to a peak of 2.25mg/dl after the end of therapy. NAC was
started 2 days following the end of the chemotherapy protocol at a dose of 600mg BID
and was given for 5 days. Following treatment, serum creatinine declined to 1.12mg/dl,
levels which were lower than observed creatinine levels at the start of treatment [45].
5.2.2.2.1 CASE REPORT
A 4-year-old girl was diagnosed with poorly differentiated epithelial Wilms
tumor of favorable histology in April 2010. The tumor was stage 3 due to periaortic
node involvement. She received radiation and AREN0532 protocol treatment. In May
2012 she had a relapse surrounding the pulmonary artery, which was confirmed by
biopsy. She was started on ICE (Ifosfamide /Carboplatin /Etoposide) protocol and
Topotecan/cyclophosphamide therapy for recurrent Wilms tumor. She received four
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cycles of treatment with ICE, which included 5 days of 1.8g/m2 of IFO admixed with
MESNA 360 mg/m2 over 2 hours daily for 5 days. During the 4th cycle, her serum
creatinine remained in the range of 0.4-0.6 mg/dl during the ICE administration (day 15) but steadily began to increase following discharge on day 6 to a peak of 1.7mg/dl on
day 10, when she was admitted to hospital for suspected sepsis (Figure 1). Following
admission antibiotics (meropenum and vancomycin) and IV hydration were started.
NAC was started on day 11 and was continued for 5 day at a dose of IV 1g per day.
Following NAC administration, serum creatinine levels began to fall and within 1 week
were within the normal ranges. Although suspected sepsis could have resulted in renal
injury, and therefore its treatment in renal improvement, sepsis was ruled out as blood
and urine cultures were negative. This would indicate the presence and treatment of
sepsis was not responsible for changes in renal function. With respect to hydration
status, following rehydration the patient did show slight improvement in serum
creatinine, however her levels were still abnormally high suggesting kidney injury could
not be ruled out. After starting NAC, there is steep decrease in creatinine values and
clinical improvement, improvements which were not seen with rehydration. This would
suggest improvements were due at least in part to NAC therapy, as renal dysfunction is
multfactorial. Although her condition improved, the decision was made to withhold the
5th cycle of ICE. She continues her chemotherapy now with topotecan and
cyclophosphamide only; all evidence to date suggests successful treatment of her
cancer. She does not have any evidence of metastatic disease and her renal function
remains within normal limits.
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Currently there is no available approved drug to treat or prevent nephrotoxicity
caused by IFO. There is however a good body of evidence, presented above, which
suggests both the safe and effective use of NAC for treatment and prevention purposes.
While a RCT is most certainly necessary to determine its effectiveness, we believe there
is sufficient evidence to use NAC in cases where nephrotoxicity is already present;
evidence which includes 3 case reports of children who were successfully treated with
NAC for nephrotoxicity which presented during treatment, and whose chemotherapy
was successful. Given that there are no alternative options, we believe it is irresponsible
not to provide these children with the best possible chance they have to restore their
renal function, especially in consideration of the minimal risk associated with NAC
therapy and the potential enormous benefits. While we understand physicians may be
reluctant to treat every child who requires IFO with NAC, we believe that until an RCT
is carried out, the use of NAC is justified if and when nephrotoxicity is present.
Following an RCT evaluating NAC given as standard adjuvant to IFO therapy, much in
the same way MESNA is given for uroprotection, we would suggest NAC may be more
appropriately used and accepted for prophylaxis.
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Figure 5.1 Serum creatinine levels of 4-year old suffering from Wilms tumor.
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5.2.3 Clinical protocol recommendations
The following guidelines have been developed with input from scientists,
clinical pharmacologists and practicing physicians including nephrologists and pediatric
oncologists. This section outlines the basic steps and considerations when treating
kidney toxicity associated with IFO treatment.
5.2.3.1 Who should be treated? Grading nephrotoxicity
Adolescents and children who present to oncology with cancer requiring treatment
with IFO should have baseline kidney function assessed. Both glomerular and tubular
function should be assessed by measurements of serum creatinine, electrolytes,
phosphate, bicarbonate, calcium magnesium and pH, and urinary glucose and protein.
Patients should also have renal function assessed immediately and 1 week following
each IFO containing cycle and immediately before each subsequent cycle begins.
Follow up after completion of therapy should occur at 1 week, 3 months and 1 year to
continue to monitor renal function. Patients declines of renal function can be measured
one of two ways:

1-

Using the following five criteria described by Lobstein et al. [47] with

modifications, to defined abnormal renal function:

1) Hypophosphatemia (<2 SD for age)
2) Hypocarbia together with metabolic acidosis (bicarbonate<18mEq/L together
with pH<7.32)
3) Glycosuria (any amount)

170
4) Proteinuria (1.0 g/L or greater)
5) Measured or estimated glomerular filtration rate (GFR) and/or creatinine
clearance (CrCl) are < 80 ml/min/1.73m2.*
* measured by isotopic nuclear GFR measurement, measured by
creatinine clearance, estimated by creatinine-based equations (such as modified
Schwartz formula), estimated by cystatin C-based equations or others

Each criterion is to be considered only if it appears as normal in the baseline
renal function assessment and became abnormal following the start of IFO and
only if it appeared as abnormal at least twice.

The patient can be classified in one of four categories based on their degree
of nephrotoxicity (Table 5.1):
OR
2-

As estimations of GFR by creatinine are often underestimated when patient

creatinine levels are not in steady state, renal injury can be assessed according to
pRIFLE criteria [48] (Table 5.2):
Any patient categorized as mildly, moderately or severely nephrotoxic, OR who
meets any pRIFLE criteria of should be treated with NAC.
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Table 5.1 Degree of nephrotoxicity based on Lobestein et al. [47] criteria.
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Degree of

# of Abnormal

Nephrotoxicity

Criteria Met

Non-nephrotoxic

None

Mildly nephrotoxic

1

Moderately

2-3

nephrotoxic
Severely
nephrotoxic

4-5
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Table 5.2 pRIFLE criteria.
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Estimated CCL

Urine Output

Risk

eCCl decrease by 25%

<0.5 ml/kg/h for 8 h

Injury

eCCl decrease by 50%

0.5 ml/kg/h for 16 h

Failure

eCCl decrease by 75%

<0.3 ml/kg/h for 24 h

or eCCl <35 ml/min/1.73 m

or anuric for 12 h

Loss

Persistent failure >4 weeks

Endstage End-stage renal disease (persistent
failure >3months)
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5.2.3.2 How should n-acetylcysteine be given?
While both oral and IV NAC are approved protocols (for acetaminophen
overdose) the use of IV NAC is recommended for the indication of renal protection for
several reasons. Oral NAC has a low oral bioavailability of 4-10% [49], therefore a
greater systemic dose can be achieved with IV NAC, even when total oral dose is much
higher (Table 5.3). Furthermore oral NAC has a high rate of nausea and vomiting as a
side effect making it difficult know what dose, if any at all, was administered [37].
However most importantly, the 21-hour IV dose that can be given safely provides the
highest systemic dose, therefore assuring the patient has the highest level of renal
protection.
As IFO cycles can range for 2-5 days [50], it is recommended that NAC be given
in the 21-hour IV dose on all days following IFO administration. While no studies exist
using repeated administration of the 21-hour IV protocol, as discussed above, oral NAC
is routinely given daily for up to 6 month without any serious adverse events [42]. The
21-hour IV protocol is as follow should be administered as follows:

For patients over 40kg [51](Table 5.3):

For patients under 40kg [52](Table 5.4):
The 200mg/mL solution of NAC should be diluted to 40mg/mL with D5W to avoid
excessive free water leading to hyponatremia and seizures.
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Renal function should be measured each day following IV NAC and 1 week
following completion of treatment. Ifosfamide treatment can be continued with special
attention being paid to monitoring for changes in renal function. Concomitant NAC
treatment should be considered in all future IFO therapy as a preventative measures.
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Table 5.3 21-hour intravenous protocol for NAC.
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Dose

Volume of

Time

D5W
1

150 mg/kg

200mL

15-60 minutes

2

50 mg/kg

500mL

4 hours

3

100 mg/kg

1000mL

16 hours
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Table 5.4 Dilution of 21-hour IV NAC protocol for patients under 40kg.
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Infusion

Dose

1

0.75 ml/kg of NAC 200 mg/ml in 3 ml/kg of D5W with maximum of 200 ml of
D5W administered over 1h

2

0.25 ml/kg of NAC 200 mg/ml in 10 ml/kg of D5W with maximum of 500 ml of
D5W administered over 4h

3

0.5 ml/kg of NAC 200 mg/ml in 20 ml/kg of D5W with maximum of 1000 ml of
D5W administered over 16h
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5.2.3.3 Measurement of tumor response
Tumor response should be evaluated according to Jurgens et al. [4].
Tumors should be assessed for response with X-ray and/or computerized axial
tomography at the end of treatment and will be classified as follows:
1)

Complete remission: Lack of measureable evidence of disease

2)

Partial remission: regression of more than 50% of tumor size

3)

Non-responder: regression of less than 50% of tumor size and progressive disease

5.2.4 Considerations of n-acetylcysteine usage
Several considerations should be given when using NAC treatment for IFOinduced renal toxicity.
5.2.4.1 Dose and route of administration
IV NAC is the preferred treatment option as it is the standard protocol currently
used by most and because it provides a higher systemic exposure, therefore ensuring the
highest NAC dose possible. However, there may also be circumstances in which
administration of IV NAC is either not practical or not possible. Under such
circumstances we would recommend the use of oral NAC as opposed to no treatment at
all. Our second case report suggests that the systemic doses achieved with oral NAC can
be sufficient in providing renal protection. In such circumstances we recommend the
use of 600mg BID in order to provide the patient with a minimum amount of renal
protection. However, we again re-iterate, IV NAC is the preferred treatment option as it
is the standard protocol used by most and because it provides a higher systemic
exposure, therefore ensuring the highest NAC dose possible.
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5.2.4.2 Adverse drug reactions
As previously discussed, there exists the potential for adverse drug reactions
(ADRs) when using NAC, most commonly anaphylactoid reactions when
administration is IV. Following presentation of such a reaction, we recommend
following the guidelines published by Bailey et al. [41]. These guidelines are based on
a 6-year retrospective case series and a literature review, and were assessed
prospectively in a poison centre. Following an anaphylactoid reaction, they recommend
reassessing the need for NAC. Should it be deemed necessary, they suggest IV
administration of diphenhydramine 1mg/kg (maximum 50mg); NAC may be restarted 1
hour after [41].
5.2.4.3 Other
IFO is commonly given in combination therapy either as part of the ICE
protocol including IFO, carboplatin and etoposide as well in combination with
etoposide alone. It is important to be aware that work exploring the effects of NAC on
both these chemotherapeutic agents has been assessed in animal models. These studies
demonstrated that NAC had no effect on the antineoplastic effects of either carboplatin
or etoposide [53]. Second, while the ideal patient treated with NAC would present only
suffering from nephrotoxicity caused by IFO and would be treated with IV NAC during
their IFO cycle, pediatric oncology is far from ideal. Patients may present with
declining renal function as a result of previous treatment with nephrotoxic drugs, such
as platinums or methotrexate. Under these circumstances, treatment with NAC is still
recommended. As demonstrated in two of the case reports, a patient may present with
declining renal function prior to any treatment with IFO. In both cases recovery of
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kidney function was observed even when the primary renal insult may not have been
IFO. Furthermore, renal dysfunction may develop following the completion of all IFO
cycles, therefore preventing the administration of NAC during the IFO cycle as
recommended above. As evidenced in 2 of the described cases, NAC also provided
renal protection even after the IFO cycle was completed, suggesting children will still
benefit from NAC therapy even when administration is delayed. We would therefore
still recommend that patients with delayed onset of nephrotoxicity be administered a
least one course of the 21 hour IV dose of NAC.
5.2.5. Future directions
The ultimate goal of NAC therapy would be to provide patients with renal
protection, much in the way that MESNA is currently always given alongside IFO; or at
a very minimum to susceptible individuals once the means of identifying them becomes
available. The future direction of NAC therapy includes a RCT designed to assess the
effectiveness of NAC as a prophylactic strategy for IFO-induced nephrotoxicity. In the
meantime, NAC rescue therapy is the most promising strategy available to patients and
is an important consideration in the maintenance of the health and well being of the
patient.

5.3. N-acetylcysteine as a prophylactic strategy against nephrotoxicity in children
caused by ifosfamide; a randomized control trial protocol
5.3.1 Rationale
NAC is currently used clinically in children for acetaminophen overdose [33,
54, 55]. With this in mind it is clear that NAC is an excellent candidate in the
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prophylactic treatment of renal toxicity caused by IFO, as safety and efficacy in
children has been established. Children are a population for which this data is often
limited and difficult to obtain. The availability of this data for NAC allows for a
relatively short amount of time until it can be used, while compounds for which this
data is not known would take many years to be realized clinically. NAC would provide
immediate treatment of IFO-nephrotoxicity following evidence suggesting it will
provide renal protection during IFO therapy. The current protocol used worldwide is the
21-hour IV protocol consisting of infusion of 150mg/kg over 60 minutes, 50 mg/kg for
4 hours and finally 100mg/kg for another 16 hours providing a total dose of 300mg/kg
[54, 56]. In the past other protocols, providing both greater and lower total doses have
been explored and used in the treatment of acetaminophen overdose and include a 72
and 36 hour oral dose and a 48 hour IV dose (Table 2.1).
To test the ability of NAC to protect against IFO-induced nephrotoxicity in a
pediatric population, we propose to conduct a randomized controlled trial during which
children receiving IFO therapy will be randomly assigned to one of two groups, one
receiving IFO only and the other receiving IFO and concurrent NAC treatment.
Preliminary data suggesting the effectiveness of NAC in the treatment of nephrotoxicity
caused by ifosfamide includes 3 case reports, summarized above in supporting evidence
section of the NAC rescue protocol. These cases suggestion NAC is effective in
providing treatment of renal toxicity during IFO therapy. However, before NAC can be
approved for use in a clinical setting, its effectiveness must be shown in a controlled
fashion that we propose to do with a RCT.
5.3.2 Hypothesis and aim
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NAC, in the 21-hour IV formulation used for acetaminophen overdose, given as
adjuvant to IFO chemotherapy, will decreased the incidence of nephrotoxicity in
children being treated for their cancer.
Our aim is to examine the effectiveness of NAC in the prevention of IFOinduced nephrotoxic adverse events.
This study will provide evidence to support or counter the introduction of the
21-hour IV NAC dose, as standard of care, for children receiving IFO treatment.
5.3.3 Experimental approach
This phase III multicentre prospective double-blinded RCT will compare the
effectiveness of the 21-hour IV protocol of n-acetylcysteine as a prophylactic treatment
against renal dysfunction resulting from IFO.
5.3.3.1 Study design
In this randomized controlled trial, participants will be randomized according to
block randomization. There will be four blocks represented by each cancer type in
which patients will be assigned randomly to receive NAC concomitantly with IFO and
MESNA infusion or to receive a placebo saline infusion. 100 patients will be
randomized to each arm (total 200). Both patient and clinician will be blinded to
treatment received.
5.3.3.2 Study population
Children and adolescents diagnosed with osteosarcoma, Ewing’s sarcoma, acute
lymphoblastic leukemia and non-Hodgkin’s lymphoma, where IFO will be included in
their chemotherapy treatment will be eligible for participation. Written, informed
consent will be obtained from parents and legal guardians of all participants under the
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age of 18. Assent will be obtained in all children over the age of 7. Patients will be
recruited from the Division of Haematology/Oncology out of the Department of
Pediatrics from both the Hospital for Sick Children in Toronto, Ontario and the London
Health Sciences Centre in London, Ontario. Ethical approval will be obtained from
institutional research ethics boards at both sites.
5.3.3.3 Inclusion criteria
1. Primary diagnosis with osteosarcoma, Ewing’s sarcoma, acute lymphoblastic
leukemia and non-Hodgkin’s lymphoma treated with IFO alone or IFO in
combination therapy
2. Between the ages of 0-21
3. Written informed consent from parent or guardian, or patients where
applicable
4. Assent from children over the age of 7
5.3.3.4 Exclusion criteria
1. Prior or current renal dysfunction
2. Hepatic dysfunction
3. Prior chemotherapy
4. Failure to obtain a written consent/assent
5. Participation in other clinical trials
5.3.3.5 Primary Endpoints
Renal function: Renal function will be assessed as per protocol by Loebstein et al.
[47].
Glomerular filtration: Shwartz formula, the ratio of height to plasma creatinine
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(80 mL/min/1.73 m2 as the lower limit of normal values.)
Tubular function: serum concentration of electrolytes, phosphate, bicarbonate,
calcium, magnesium and serum pH, and glycosuria and protienuria as assessed
through spot urine sample.
The following five criteria were used to define abnormal renal function:
1) Hypophosphatemia (<2 SD for age)
2) Hypocarbia together with acidosis (bicarbonate<18mEq/L together with
pH<7.32)
3) Glycosuria (any amount)
4) Proteinuria (1.0 g/L or greater)
5) Decreased creatinine clearance (80 mL/min/1.73 m2).

Each criterion was considered only if it appeared as normal in the baseline renal
function assessment and became abnormal following the start of IFO and only if it
appeared as abnormal at least twice. Each patient will be classified in one of four
categories based on their degree of nephrotoxicity:
Non-nephrotoxic: no abnormal criteria recorded
Mildly nephrotoxic: one abnormal criterion recorded
Moderately nephrotoxic: 2-3 abnormal criteria
Severely nephrotoxic: 4-5 abnormal criteria

Tumor response: Tumor response will be evaluated according to the criteria of Jurgens
et al. [4]. Tumors will be assessed for response with X-ray and/or computerized axial
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tomography at the end of treatment and will be classified as follows:
Complete remission: Lack of measureable evidence of disease
Partial remission: regression of more than 50% of tumour size
Non-responder: regression of less than 50% of tumor size and progressive
disease
5.3.3.6 Methodology
Following enrollment into the clinical trial, the patient and their parents will
meet with the study coordinator at the Hospital for Sick Children or London Health
Sciences Centre, 1 week prior to starting chemotherapy treatment. During this meeting,
the study coordinator will become familiar with the patient and their family, providing
them with information regarding the study, answering any questions the have in a
private setting. Following consent to participate, a trial nurse will draw blood in order to
assess baseline kidney function, as well as rule out any the presence of any exclusion
criteria.
During chemotherapy treatment, the 21-hour IV NAC protocol or placebo will
be given each day immediately following the chemotherapy session including IFO.
Kidney function will be reassessed at the end of each chemotherapy cycle, as well as
prior to the start of the next IFO containing cycle. Tumor response will be measured at
the end of each cycle. Follow-up appointments, which will include measuring kidney
function and tumor response, will occur every 3 months for 24 months, and every 6
months thereafter. Trial follow-up will end 3 years post-treatment.
Patients, who continue to suffer from grade 2 nephrotoxicity or higher for more
than two successive renal function tests, will be switched to protocol containing less
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nephrotoxic drugs and their nephrotoxicity treated according to the institutional
standard of care.
Patients, who suffer from an anaphylactoid reaction resulting from IV NAC, will
be given 1mg/kg of IV diphenhydramine (maximum 50 mg); one hour after NAC
infusion can be resumed. This treatment is according to recommendations on how to
manage anaphylatoid reactions caused by NAC [41]. Supportive care for all
chemotherapy side effects will be treated as per the institutions standard of care.
5.3.3.7 Sample size and statistical calculations
A sample size of 50 per group was calculated a priori and designed to detect a
clinically significant decrease in incidence of nephrotoxicity from 30% to 15% with
80% power and alpha of 0.05. This was defined by expert consensus as being clinically
significant through consultation with clinicians and is based on the current rate of
nephrotoxicity with current treatment protocols. Proportions will be compared by Chi
square or Fisher exact test.
5.3.4 Ethical considerations
This study has been discussed and received input from practicing oncologists,
nephrologists, and pharmacologists. While it may result in a small increase in baseline
risk due to the chance of anaphylactoid reaction associated with IV NAC, this adverse
event is non-life-threatening, is easily treated, and is less serious than nephrotoxicity;
therefore its potential benefit in preventing nephrotoxicity far outweighs the risk
associated with an anaphylactoid reaction. Due to the nature of oncology, and the
timeliness with which treatment must commence, the study is discussed with patients
one week prior to the start of therapy under non-stressful conditions. With the exception

190
of the baseline kidney function test, all blood sampling will be obtained as a part of
routine care, which would occur regardless of enrollment in the trial.

5.4 Overall discussion and future directions
80% of children will survive their cancer; however, two-thirds of those who
have survived their childhood cancer will suffer health problems secondary to their
cancer treatment. This is a significant number of people who are unnecessarily suffering
an impaired quality of life. These late effects can be protected against provided the
opportunity to research prophylactic and treatment strategies. The use of
chemoprotectants as means to prevent side effects caused by chemotherapy is not new.
In oncology, these late effects are merely the cost of successful cancer therapy. In
regards to IFO, treatment of these late effects has come a long way. MESNA is
routinely given alongside IFO therapy in order to prevent urotoxicity and a wealth of
information suggests NAC will prevent nephrotoxicity.
In order to identify NAC as a potential treatment strategy for nephrotoxicity
associated with IFO, the first step is to understanding its role in kidney toxicity.
Identifying CAA the nephrotoxic metabolite, allows for a clear definition of the
mechanism through which the kidney was damaged; oxidative stress, suggesting a clear
direction for potential treatment and prevention options. Antioxidants appear to be a
logical solution to a problem resulting from oxidative damage. Further to that end, nacetylcysteine, with its current use in children appears the most reasonable choice in a
long list of antioxidant compounds. Equipped with a well-chosen candidate for renal
protection, demonstrating the efficacy of NAC in both cell and animal models is the
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next step in continuing this translational research. The studies described in this thesis
provide the final step in defining a treatment that will allow for prevention of renal
damage caused by ifosfamide treatment.
The work involving NAC truly has gone through the evolution of bench to
bedside. Beginning with a lack of knowledge surrounding how nephrotoxicity might
occur, to then a clear picture of the mechanisms involved, enabled potential treatment
strategies to become clear. This will significantly impact the health of those at risk for
developing nephrotoxicity. However it might also serve as an example and provide
insight into the prevention of other late effects resulting from cancer therapy.
With respect to future work, there is still more that can be done to achieve a
better understanding of nephrotoxicity. It is likely that genetics play some role in
deciding which children will be affected by nephrotoxicity. Therefore we suggest future
studies include assessing genetic variability that may contribute to the risk of
developing nephrotoxicity. Aldehyde dehydrogenase, which is responsible for
deactivation of CAA to chloroacetate in the tubule cells shows variability with both
high and low expressing polymorphisms [57-59].This information could define clearer
strategies for use of NAC during IFO therapy such that only children at risk for or
displaying signs of renal dysfunction will be given this treatment.
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Appendix 4: Plasma AUC of NAC of patients treated for acetaminophen overdose
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Appendix 4.1 The systemic exposure of NAC in subject 2, receiving the standard NAC
intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100 mg/kg
for 16 hours. AUC is 20.57 mM·h, where the dotted line represents the residual area
calculated.
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Appendix 4.2 The systemic exposure of NAC in subject 3, receiving the standard NAC
intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100 mg/kg
for 16 hours. AUC is 17.58 mM·h, where the dotted line represents the residual area
calculated.
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Appendix 4.3 The systemic exposure of NAC in subject 4, receiving the standard NAC
intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100 mg/kg
for 16 hours. AUC is 8.01 mM·h, where the dotted line represents the residual area
calculated.
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Appendix 4.4 The systemic exposure of NAC in subject 7, receiving the standard NAC
intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100 mg/kg
for 16 hours. AUC is 10.93 mM·h, where the dotted line represents the residual area
calculated.
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Appendix 4.5 The systemic exposure of NAC in subject 8, receiving the standard NAC
intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100 mg/kg
for 16 hours. AUC is 6.22 mM·h, where the dotted line represents the residual area
calculated.
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Appendix 4.6 The systemic exposure of NAC in subject 9, receiving the standard NAC
intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100 mg/kg
for 16 hours. AUC is 7.46 mM·h, where the dotted line represents the residual area
calculated.
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Appendix 4.7 The systemic exposure of NAC in subject 11, receiving the standard
NAC intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100
mg/kg for 16 hours. AUC is 13.27 mM·h, where the dotted line represents the residual
area calculated.
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Appendix 4.8 The systemic exposure of NAC in subject 13, receiving the standard
NAC intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100
mg/kg for 16 hours. AUC is 16.95 mM·hr, where the dotted line represents the residual
area calculated.
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Appendix 4.9 The systemic exposure of NAC in subject 14, receiving the standard
NAC intravenous protocol, 150 mg/kg for 60 minutes, 50 mg/kg for 4 hours, and 100
mg/kg for 16 hours. AUC is 10.38 mM·hr, where the dotted line represents the residual
area calculated.
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